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Complex intensity modulated fields delivered by means of rotational dynamic techniques, such as
Volumetric Modulated Arc Therapy (VMAT), can provide demanding dose distributions in short
irradiation times and fewer monitor units. However this dynamic implementation involves two
main sources of uncertainty: one related to the dose calculation accuracy, and the other linked to
the continuous delivery of a discrete calculation. Therefore, require new quality assurance (QA)
protocols and detailed verification capable of predicting the actual delivered dose to the patient.
This is especially critical when used with hypofractionated schemes and for stereotactic body
radiotherapy (SBRT) treatments. In this scenario, Monte Carlo (MC) simulation presents an
ideal tool to complete the linac commissioning required for VMAT, as well as the gold standard
for dose distribution verification. The present thesis reflects the work carried out in order to
implement a routine MC verification of VMAT treatments, and to develop a QA model able to
control and potentially reduce the inherent uncertainties for a fair and reliable evaluation of
current VMAT solutions, including further evaluation of VMAT QA systems. The developed
model consists on a system composed by a specific phantom integrated with MC simulation of
VMAT log files in a feedback procedure by implementing an optimization process able to adjust
the Monitor Units and reconstruct the dose-volume histogram on the patient CT.
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Abstract 
 
Complex intensity modulated fields delivered by means of rotational dynamic 
techniques, such as Volumetric Modulated Arc Therapy (VMAT), can be 
considered a step forward in comparison to conventional, static technique, 
providing demanding dose distributions in short irradiation times. However this 
dynamic implementation involves two main sources of uncertainty: one related 
to the dose calculation accuracy, and the other linked to the continuous delivery 
of a discrete calculation. Therefore, require new quality assurance (QA) 
protocols and detailed verification capable of predicting the actual delivered dose 
to the patient. This is especially critical when used with hypofractionated 
schemes and for stereotactic body radiotherapy (SBRT) treatments. In this 
scenario, Monte Carlo (MC) simulation presents an ideal tool to complete the 
linac commissioning required for VMAT, as well as the gold standard for dose 
distribution verification.  
The present thesis reflects the work carried out in order to implement a 
routine MC verification of VMAT treatments, and to develop a QA model able to 
control and potentially reduce the inherent uncertainties for a fair and reliable 
evaluation of current VMAT solutions, including further evaluation of VMAT 
QA systems. The developed model consists on a system composed by a specific 
phantom integrated with MC simulation of VMAT log files in a feedback 
procedure by implementing an optimization process able to adjust the Monitor 
Units and reconstruct the dose-volume histogram on the patient CT.  
Several clinical cases, previously planned with different treatment planning 
systems and verified with different commercial solutions were selected in order 
to test operational feasibility of the proposed model. The proper operation of the 
feedback procedure was proved through the achieved high agreement between 
reconstructed dose distributions and the film measurements. The proposed 
model showed to be valid for VMAT assessment, and also for linac 
commissioning and evaluation of other QA systems. Besides, the results also 
showed enough robustness and efficiency of the model to be considered as a pre-
treatment VMAT verification system. 
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Resumen 
 
Los tratamientos de radioterapia con intensidad modulada, impartidos por 
medio de técnicas dinámicas rotacionales, como es el caso de la arcoterapia 
volumétrica modulada (VMAT, del inglés Volumetric Modulated Arc Therapy), 
pueden ser considerados un avance en relación a la técnica estática 
convencional, proporcionando distribuciones de dosis complejas en tiempos de 
irradiación más cortos.  Sin embargo, esta implementación dinámica involucra 
dos principales fuentes de incertidumbre: una relacionada a la precisión del 
cálculo de la dosis, y otra asociada a la impartición continua de un cálculo 
discreto. Esto requiere nuevos protocolos de control de calidad (QA del inglés 
Quality Assurance) y una verificación detallada, capaz de estimar la dosis que 
recibirá el paciente. Esto es especialmente importante cuando se emplea esta 
técnica en tratamientos bajo esquemas hipofraccionados o de radioterapia 
estereotáxica extracraneal (SBRT del inglés Stereotactic Body Radiotherapy). En 
este escenario, la simulación Monte Carlo (MC) se presenta como una 
herramienta ideal para completar la puesta a punto del acelerador lineal 
requerido para la VMAT, así como la referencia estándar para la verificación de 
la distribución de dosis.  
El presente trabajo se ha llevado a cabo con el fin de implementar una 
verificación MC rutinaria de tratamientos de VMAT, y desarrollar un modelo de 
QA para controlar y, potencialmente, reducir las incertidumbres inherentes para 
una evaluación justa y fiable de las soluciones de VMAT actuales. El modelo 
desarrollado, consiste en un sistema compuesto por un maniquí específico 
integrado con la simulación MC de los ficheros log de VMAT, en un 
procedimiento de retroalimentación, a través de un método de optimización 
capaz de ajustar las unidades monitor para reconstruir, experimentalmente, el 
histograma dosis-volumen en la imagen del paciente.  
Varios casos clínicos, previamente solucionados con diferentes sistemas de 
planificación y verificados con distintas soluciones comerciales, fueron 
seleccionados para poner a prueba la viabilidad operativa del modelo propuesto. 
 xii 
El funcionamiento correcto del procedimiento de retroalimentación se demostró 
a través del alto acuerdo alcanzado entre las distribuciones de dosis 
reconstruidas y las medidas en película. El modelo propuesto mostró ser válido 
para la evaluación de la VMAT, para llevar a cabo la puesta a punto del linac, e 
incluso para evaluar otros sistemas de QA. Además, los resultados obtenidos 
también mostraron que el modelo es suficientemente robusto y eficiente para su 
aplicación clínica, como sistema de verificación pre-tratamiento de VMAT. 
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Chapter 1 
Introduction 
 
Nowadays, radiotherapy is a prominent and widely used modality of cancer 
treatment, often in combination with surgery and/or chemotherapy. In broad 
terms, radiotherapy exploits the fact that ionizing radiation produce damage to 
tumor cell’s DNA (both directly and indirectly via free radical production) and 
can lead to cell death. Unfortunately, the same is true for healthy cells 
surrounding the tumor. The main goal of radiotherapy, therefore, is to increase 
cell kill in tumors while minimizing it in healthy tissues, such that acute and 
late side‐effects can be reduced. 
According to data provided by GLOBOCAN, about 14.1 million new cancer 
cases were estimated to have occurred in 2012 worldwide (Ferlay et al., 2015), 
and about half of these cases were or will be undergo radiotherapy  in some of 
the treatment phases (Delaney et al., 2005). Although cancer is a leading cause 
of death worldwide, with 8.2 million deaths estimated for 2012 (Ferlay et al., 
2015), the 5-year survival rate for all diagnosed cancers has been improved over 
the years due to advances in early diagnosis and treatment. 
In the past few decades, radiotherapy techniques have improved drastically 
along with important advances in technology and imaging techniques, 
increasing the accuracy, flexibility and efficiency of beam delivery. These 
developments have been mainly driven by the need to reduce the dose to normal 
tissue structures and thereby minimize the risk of toxicity and morbidity, which 
then allows dose escalation to the tumor volume potentially leading to improved 
loco-regional control. The culmination of these modern developments has been 
the intensity modulated radiotherapy (IMRT), which has widened the horizons 
of radiotherapy due to its ability to conform radiation dose distributions to 
complex tumor target volumes while sparing nearby critical structures as much 
as physically possible. This is reached by the delivery of an optimized non-
uniform fluence (Webb, 2000). The radiation fields with high non-uniform 
intensities are sometimes needed to create the prescribed uniform dose to the 
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target volume. This is the case for obtaining homogeneous concave dose 
distributions, as it was first recognized and described by Brahme et al. in 1982 
(1982).  
The non-uniform fluence can be achieved either by intercepting the beam 
with physical filters of varying thickness (compensators) or by changing beam 
aperture, usually created by a multi-leaf collimator (MLC) (e.g. by dividing the 
field into segments of varying weights). The latter can be performed with static 
or rotating gantry. Techniques with fixed gantry are delivered in either dynamic 
mode, in which leaves move while the radiation is on (sliding window mode), or 
static mode (step-and-shoot mode), in which the beam is held off while the MLC 
leaves move (“step”) and is turned on when they reach their pre-defined static 
positions (“shoot”).  
Although IMRT offers optimal dosimetric results, a few undesirable aspects of 
this technique have to be taken into account. These include increased treatment 
times, considerable rise in number of delivered monitor units (MUs) and the 
need for more extensive quality assurance (QA) checks than for conventional 
techniques (Mijnheer and Georg, 2008). Moreover, in the most usual techniques 
of IMRT a large volume of normal tissue can receive low doses of radiation, what 
increases the potential late effects of a big number of patients treated with 
IMRT and the risk of secondary cancers (Hall and Wuu, 2003; Palma et al., 
2010). This is of particular concern in the case of pediatric patients.  
All these considerations have led to an increased interest in arc-based or 
rotational techniques for delivery the modulated intensity, such as volumetric 
modulated arc therapy (VMAT), in pursuit of delivery demanding dose 
distributions, in shorter treatment times and potentially fewer MUs compared 
to conventional static field IMRT. Moreover, it is expected to decrease the low 
dose radiation to surrounding normal tissue, which potentially would decrease 
the risk of secondary malignancy (Teoh et al., 2011), although this could not be 
observed in all situations (Abo-Madyan et al., 2014). 
 
Throughout this first introductory section an overview of the rotational IMRT 
techniques including tomotherapy, on one hand, and intensity modulated arc 
therapy (IMAT), on the other hand will be included. A brief historical review of 
the works leading to the wide adoption of VMAT and comparisons with other 
IMRT delivery techniques will be discussed. Considerations for clinical 
implementation and VMAT quality assurance (QA) will be also included, in the 
context of this thesis, and finally the hypothesis and the aims will be described. 
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1.1 Intensity Modulated Arc Therapy  
Among the rotational alternatives proposed for the delivery of IMRT, two 
dominant but different approaches have emerged, depending on the beam type 
delivered. Based on the original ideas of Brahme el al., Mackie et al. (1993) 
proposed a rotational approach called tomotherapy in which intensity modulated 
photon therapy is delivered using a rotating fan beam. Intensity modulation is 
achieved through the use of a dedicated system that incorporates a temporally 
modulated slit multileaf collimator revolving around the patient. Either the 
patient is moved between successive rotations (serial tomotherapy) or 
continuously during rotation called helical tomotherapy (HT). For the latter, the 
system looks like a conventional CT scanner and includes a megavoltage portal 
detector to provide the reconstruction of the CT images. Contrary to common 
belief, historically, clinical IMRT by tomotherapy preceded clinical IMRT by any 
MLC-based technique.  
In 1995, Yu (1995) introduced an alternative approach to the delivery of 
rotational IMRT using a cone beam of radiation, called intensity modulated arc 
therapy (IMAT). A key difference from tomotherapy is that IMAT can be 
delivered using a conventional linear accelerator (linac) and a conventional (non-
binary) MLC. IMAT is a multiple arc technique in which the aperture defined by 
multi-leaf collimator changes dynamically while gantry rotation speed and dose 
rate remain constant (Meyer, 2011). The degree of intensity modulation is 
related to the number of beam shapes per arc and the total number of arcs (Yu 
and Tang, 2011). 
Several clinical studies were conducted to implement IMAT for different 
treatment sites (Duthoy et al., 2004; Wong et al., 2005; Yu et al., 2002). 
Nevertheless, as a clinical tool, the IMAT technique did not mature into clinical 
application. The possible reasons could be found in the lack of an efficient 
planning method for IMAT and the lack of commercial interest at that time. The 
linac manufacturers did not offer delivery control systems that were capable of 
taking full advantage of the IMAT delivery technique. 
The IMAT technique did evolve by increasing the number of variable 
parameters. By assuming that the machine dose rate can vary as needed, Otto 
(2008) developed a single-arc IMAT algorithm that he named as volumetric 
modulated arc therapy (VMAT). In addition to allowing dose rate and gantry 
speed variation, the VMAT algorithm used progressive beam angle sampling to 
optimize a large number (greater than 100) of apertures using direct aperture 
optimization. 
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The major conceptual advantage of VMAT over standard fixed-field IMRT 
techniques is that the rotational nature of the delivery can provide more 
flexibility in terms of shaping the dose distributions, and time is used efficiently 
because the radiation delivery does not stop in between different beam angles 
(Otto, 2008).  
1.2 Commercial implementation of VMAT 
In recent years, manufacturers of medical linacs and developers of treatment 
planning systems (TPS) have introduced products for rotational IMRT. The 
availability of more advanced delivery control systems and robust inverse 
planning solutions have made it possible to realize the full potential of IMAT as 
a delivery technique.  
In 2008, both Elekta and Varian introduced new delivery control systems 
that were capable of delivering IMAT. The critical innovation was that the new 
control systems provided the ability to vary the dose rate and to move the MLC 
leaves with a relative velocity to the gantry during rotational beam delivery. 
Varian first commercialized Otto´s VMAT algorithm (Otto, 2008) with the 
trade name RadipArcTM, offering their complete IMAT solution including both 
their delivery control system and their RapidArc module implemented in the 
Eclipse TPS solution. Varian RapidArc has been marketed primarily as a single 
arc solution but more recently, in order to get better modulation effect, has 
added support for multi-arc IMAT deliveries. On the other hand, Elekta has 
adopted the generic term VMAT to describe its commercial implementation.  
Bzdusek et al. (2009) introduced a rotational IMRT solution, which was 
marketed by Philips Medical Systems, Inc. with the trade name SmartArcTM. 
Also a VMAT module has been introduced for Nucletron’s Oncentra TPS, 
developed by RaySearch Laboratories (Stockholm, Sweden), which shares the 
same optimization engine used in the Philips SmartArc. Both SmartArc and 
Nucletron Oncentra IMAT planning tools can be used with either Elekta or 
Varian linacs. 
Another IMAT solution called cone beam therapy (CBT) was presented by 
Siemens, in collaboration with Prowess Inc. for integration into Siemens’ linear 
accelerators. 
Other names, such as arc-modulated radiation therapy (AMRT) (Wang et al., 
2008) and aperture modulated arc therapy (AMAT) (Crooks et al., 2003) were 
also used to describe other planning methods for single-arc IMAT.  
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Despite debate on its theoretical justifications (Bortfeld, 2010; Bortfeld and 
Webb, 2009; Otto, 2009; Verbakel et al., 2009b), VMAT has experienced a rapid 
and widespread clinical application. Consequently, various planning studies 
have been conducted in order to evaluate its benefits, in terms of plan quality 
and delivery efficiency, over more conventional IMRT forms and HT (Oliver et 
al., 2009; Palma et al., 2008; Rao et al., 2010; Verbakel et al., 2009a; Kjaer-
Kristoffersen et al., 2009). Other studies have also investigated the clinical 
applications of VMAT for a number of cases that require a greater precision and 
dose conformity (Bertelsen et al., 2010; Matuszak et al., 2010; Zhang et al., 
2010). In general, it is shown that the dosimetric results of VMAT give, at least, 
similar target coverage and preservation of organs at risk (OARs), while 
significantly reducing the number of required MUs and the overall treatment 
time. 
Shorter treatment times obviously have advantages, including greater 
patient comfort, less susceptibility of intra-session motion and possibly less 
radio-induced secondary cancers. But this efficiency must not be detrimental to 
the relative dose distribution and the integral dose. Despite theoretically 
offering greater protection to the organs at risk and present a lower maximum 
dose than other techniques, the commercial algorithms working with VMAT 
present the tendency to spread a low-dose bath larger than for fixed-field IMRT, 
which on the other hand, deposit higher doses along the paths of the individual 
beams (Kjaer-Kristoffersen et al., 2009; Mehta et al., 2009; Meyer, 2011).   
The intense commercial promotion and fast clinical adoption also caused 
much confusion and controversy. Nowadays, there is a lack of a general 
understanding of how such treatments are planned, and what delivery 
limitations are unavoidable. In order to clarify some concepts, a brief description 
of VMAT planning is included in the following sections. 
1.2.1 VMAT treatment plan optimization 
VMAT planning is complex and the potential benefits of its application 
compared to conventional IMRT are clearly dependent on the optimization 
algorithm incorporated into the TPS (Bortfeld and Webb, 2009; Otto, 2009; 
Verbakel et al., 2009b). The considerable number of dynamic delivery 
parameters need to be adequately considered by the planning system to take full 
advantage of VMAT possibilities. For example, not consider the capacity of 
changing the dose rate in the optimization algorithm will be detrimental to the 
planning. Moreover, the greater number of variables to optimize implies an 
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additional difficulty for current planning algorithms. As argued by Otto (2009) 
the challenge is in the design of optimization algorithms that fully utilize these 
degrees of freedom and generate plans that conform the dose distribution while 
being efficient in delivering the same.  
In practice, the complexity of the VMAT plan optimization can mainly be 
attributed to the need to account for the connectivity of the MLC shapes within 
an arc, since the trajectories have to fulfill constraints imposed by the machine 
limitations. The main limitations include: maximum MLC leaf seep (typical 
values are in the range of 3-6 cm/s); gantry speed constraint (typically 6°/s); dose 
rate constraints; and additional restrictions on the leaf motion depending on the 
MLC and linac models (e.g. interdigitation constraints) (Unkelbach et al., 2015). 
Constraints on the leaf motion help to ensure the accuracy of the predicted 
dose distribution. These constraints define the maximum distance a leaf can 
travel between adjacent control points (discrete segments considered in the 
optimization algorithm), which are expressed as a distance per degree of gantry 
rotation (mm/deg). Each control point (CP) is described with three major 
parameters: a gantry angle, a specific MLC shape, and a corresponding monitor 
unit value. If there are dramatic changes in the aperture shapes from one CP to 
the next, the accuracy can be compromised and the linac could execute a 
different configuration to the parameters combination planned by the TPS. Leaf 
motion constraints showed to generate a significant impact on VMAT plans in 
terms of plan quality and delivery accuracy (Chen et al., 2011). A less restrictive 
leaf motion constraint (greater than 5 mm/deg) results in improved plan quality 
but can lead to less accuracy in dose distribution, as it was evidenced by 
increasing discrepancies between the planned and the measured doses.  
As for conventional IMRT plan optimization, different methods for VMAT 
plan optimization can use either a two-step or one-step optimization process. 
Depending on the implemented method, the additional constraints on the shape 
of the apertures are enforced in different stages during the optimization process, 
resulting in different delivery efficiency.  
Traditional IMRT approaches include two stages, which were similar 
developed for VMAT. During the first stage, optimal intensity patterns are 
generated for all beams used for approximating one arc. The number of fields 
and gantry angles are defined and each beam (open field) is divided into a 
number of segments (beamlets). A search of beamlet weights is performed to 
determine the optimal beamlet weights (fluence map) such as the sum of 
weighted beamlets provide dose distribution in optimal agreement with the 
objective dose distribution. This fluence map optimization (FMO) is then 
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followed by an arc sequencing, in the second stage, where these fluence maps 
are converted to apertures into machine deliverable plans using leaf sequencing 
algorithms. Any delivery constraints of the linac are enforced in the second 
stage. This process may produce inefficient treatments and increased collimator 
artifacts (Aju-e-Taqaddas, 2011). 
One-step processes on the other hand, aim to reduce the complexity and 
overcome the problem of plan degradation. Direct aperture optimization (DAO) 
is a one-step process approach whereby all the machine delivery constraints are 
enforced directly into the plan optimization, thereby eliminating the need for a 
separate leaf sequencing step. DAO bypasses the traditional two-phase planning 
approaches by simultaneously optimizing the shapes and the weights 
corresponding to each aperture. The concept of DAO has been applied to both 
static gantry IMRT (Shepard et al., 2002) as well as VMAT (Bzdusek et al., 2009; 
Earl et al., 2003; Otto, 2008). It aids in reducing number of segments and MU 
thereby making DAO suitable for VMAT inverse planning. 
Most of the commercial VMAT planning algorithms use DAO methods in 
their optimization process. This includes RapidArc (Varian), which uses a global 
stochastic optimization approach (simulating annealing), avoiding FMO and 
sequencing methods. Contrarily of what is allowed in DAO, simulating 
annealing accepts changes in the configuration of the variables that increase the 
cost function and does not get ‘trapped’ in local minima. SmartArc (Philips) as 
well as Monaco (Elekta) implement a local gradient based optimization approach 
to DAO, and adopt FMO and arc sequencing methods to obtain a starting point 
for DAO (Unkelbach et al., 2015). 
Besides mechanical constraints, the result of VMAT optimization may also 
depend on the choice of other plan parameters (efficiency constraints), e.g. the 
number of arcs, the maximal delivery time or the gantry angle spacing between 
subsequent CPs, which defines how many CPs will be used for optimization and 
dose calculation. Thus, they should be set to achieve a good compromise between 
plan quality, dose verification agreement and treatment time.  
A dependence of the quality of the final solution on the number of starting 
CPs has been observed (Pardo Montero and Fenwick, 2011). Furthermore, the 
closer they are, in the final solution, the better is the approximation to a 
continuous arc irradiation. Therefore, the agreement of measured and calculated 
dose is expected to increase when reducing the gantry angle spacing. Feygelman 
et al. (2010) have confirmed this behavior when comparing the calculated dose 
with a large spacing of 6° between control points to a smaller spacing of 4°, 
finding less dosimetric errors in the later. 
CHAPTER 1. INTRODUCTION   
 
8 
Theoretical considerations of VMAT have focused on determining what level 
of modulation is achievable in a single arc compared to fixed field IMRT 
(Bortfeld and Webb, 2009). Bortfeldʹs work (Bortfeld, 2010) extended the theory 
that only a finite number of intensity modulated beams are required to 
approximate an ideal dose distribution. It is believed that most VMAT planning 
algorithms work using a 'small-arc approximation’ (Webb and McQuaid, 2009). 
This concept assumes that over a limited angular range (gantry angle spacing 
between CPs), and from the viewpoint of the target region, the source is 
effectively locally static and the ray paths can be approximated from a set of 
fixed angular orientations with small angular spacing. Otherwise, it would be 
too computer-time-consuming to trace the actual ray paths from continuously 
moving sources. The diagram represented in Figure 1.1 illustrates this concept. 
It can clearly be seen that from a set of unmodulated divergent VMAT fields, the 
equivalent parallel beams are spatially modulated. 
 
 
Several studies have shown that single arc VMAT can achieve dose 
distributions comparable to IMRT for prostate cancer (Palma et al., 2008; Tsai et 
al., 2011), but for more complex geometries as head and neck tumors, reports 
are contradictory. Some publications state that two or more arcs are required 
Figure 1.1. The divergent ray paths, leaf positions and segment weighting at each 
gantry angle. The reconstructed parallel rays and associated intensity-modulated 
beam are shown for every 4th angle (Webb and McQuaid, 2009). 
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(Alvarez-Moret et al., 2010; Guckenberger et al., 2009; Verbakel et al., 2009a), 
whereas Bertelsen et al. (2010) found that a single arc is sufficient to achieve 
plan quality comparable to IMRT. Beyond the theoretical discussion, in daily 
clinical practice, a balance must be made between plan quality and delivery 
efficiency that determines how many arcs should be used in VMAT planning to 
achieve the required modulation of fluence. Clearly, this task is more easily 
performed when a part of the problem is shared with another sweeping (Figure 
1.2), providing additional flexibility in shaping the dose distribution. However, 
the delivery time increases significantly, and could even becoming larger than 
for conventional IMRT. 
Unlike the technologies for optimizing conventional IMRT, this planning 
technology is not yet considered mature and completed. The current state of 
VMAT optimization was recently reviewed by some authors, who have also 
suggested some improvements (Unkelbach et al., 2015).  
 
1.2.2 VMAT dose calculation 
The general concept and process for dose calculation in VMAT planning is 
basically the same as for IMRT planning. However, due to the many degrees of 
freedom in VMAT planning, the dose calculation involved in the VMAT 
optimization process is computationally more demanding, as exposed before. 
Since most of the currently available VMAT optimization algorithms are 
based on a progressive sampling, dose calculation is performed using a 
combination of a fast dose calculation algorithm with limited accuracy, and a 
Figure 1.2. Single arc versus multiple arcs treatment optimization. Adapted from 
figure courtesy of Shepard. 
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slower but more accurate dose calculation engine for the final stage. Although 
the implementation of arc sampling and multiple dose calculation algorithms 
varies between vendors and software versions, a level of accuracy is mandatory 
in order to reach expected outcomes in tumor control and healthy tissues 
complications. It has been shown that dose differences up to 7% can be clinically 
detectable for different commercial software, while  deviations from the 
prescribed dose of 5% or more can compromise tumor response and tissue 
morbidity (AAPM, 2004; Dische et al., 1993; ICRU, 1976).  
There are many considerations in the uncertainty estimation of the dose 
delivered to the patient, hence general recommendations of dose delivery 
accuracy such as, 5% (ICRU, 1976) and 3.5% (Mijnheer et al., 1987), have been 
issued. To present an overall desired accuracy of 5% in the dose delivered to a 
volume (or point), the American Association of Physicists in Medicine (AAPM)  
recommends that the accuracy of computed dose distributions should be between 
1% to 2% (AAPM, 2004). In fact, this accuracy has increased with the 
introduction into clinical practice of improved algorithms for patient dose 
calculation, in order to better account for complex geometries and tissue 
heterogeneities.  
Most notably, the development of model-based convolution methods has 
significantly improved the accuracy of dose calculations for heterogeneous 
materials when compared to the conventional correction-based methods 
(Ahnesjo, 1989; Tillikainen et al., 2008; Ulmer et al., 2005). The limited accuracy 
of pencil beam algorithms has been thoroughly investigated. In particular, their 
ability to correctly model dose in the presence of tissue heterogeneities was 
examined, where miscalculations and significant differences with Monte Carlo 
dose calculation were reported (Cranmer-Sargison et al., 2004; Knoos et al., 
1995; Ma et al., 2000). The more accurate convolution/superposition methods use 
pre-calculated Monte Carlo dose (MC) “kernels” partly accounting for tissue 
density heterogeneities (Reynaert et al., 2007). 
The dose calculation is a problem linked to the local deposition of the energy 
of the particles in the beam and the energy associated to new particles 
generated from interactions with the linac head, the collimation system (MLC) 
and the patient. Thus, dose calculation algorithms have to take into account 
both primary and secondary radiation scatter to produce more accurate results 
in electronic disequilibrium circumstances. The high complexity of VMAT and 
other advanced techniques, based on small and irregular irradiation fields, and 
presenting regions of high dose gradients, require more accurate calculation 
than the one based on the experimental measurements concerning the standard 
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fields defined in dosimetry protocols. Moreover, density heterogeneities present 
inside the patient become critical for analytical calculation algorithms, which 
also lack precision under these dosimetric conditions (Leal et al., 2003; Reynaert 
et al., 2007; Sanchez-Doblado et al., 2007; Spezi and Lewis, 2008).  
Currently, the multiple commercial solutions for VMAT planning (e.g. Varian 
Eclipse RapidArc, Philips Pinnacle SmartArc, Elekta ERGO++, Elekta Monaco 
VMAT, Nucletron Oncentra MasterPlan VMAT, etc.) implement dose calculation 
engines with different level of robustness. With the development of computer 
hardware and variance reduction techniques for MC methods, the computation 
time was largely reduced, making MC approach feasible in some of the 
commercial TPSs (Hartman Siantar et al., 2001; Kawrakow, 2000b; Ma et al., 
1999). On the theoretical definition of VMAT presented by Otto (2008), Monte 
Carlo was already proposed as an effective and necessary tool. MC treatment 
planning (MCTP) can provide a lower uncertainty in dose calculation well within 
the 3% required for accurate radiotherapy (Reynaert et al., 2007). 
Monte Carlo dose calculation algorithms are widely recognized as the gold 
standard for calculating dose distributions once the transport of particles 
through the accelerator head and the patient heterogeneous geometry may be 
explicitly modeled. The electromagnetic particle transport is well described by 
physics using probability distribution functions. Once the probabilities of 
possible events are well described as dependent on energy and the atomic 
number of the atoms, the most accurate dose distribution has to be obtained by a 
numerical method such as Monte Carlo simulation. Residual inaccuracies may 
nevertheless exist in MC dose calculation, which are inherent to the method i.e., 
statistical noise or approximations assumed in cross-section modeling, charge 
particle condensed history algorithms, and geometrical description of the 
regions.  
Another important concern posed by the dose calculation algorithms in VMAT 
planning, is the calculation time due to the large number of beams used to 
approximate an arc. It was shown that the calculation time for MC-based 
algorithms is not so dependent of the number of beams used because the 
statistical uncertainty is linked to the total of events,  while the calculation time 
using all the empirical methods linearly increases with the number of beams 
(Tang et al., 2008). 
Recently, a new version of a deterministic grid-based Boltzmann equation 
solver (GBBS or the discrete ordinates method) was integrated in the Eclipse 
TPS as the Acuros XB algorithm to improve the efficiency and accuracy of dose 
calculations. The GBBS directly discretizes the linear Boltzmann transport 
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equation (LBTE), which governs the macroscopic behavior of particle 
interactions with matter, in space, and in angle and energy domains. The GBBS 
then iteratively solve the radiation transport problem within specified volumes 
to compute radiation doses (Han et al., 2011).  
Both MC and LBTE methods can provide convergent results for specific 
situations. The achievable accuracy is equivalent for both approaches and is 
limited only by uncertainties in the particle interaction data (cross sections 
data) and uncertainties in the problem being analyzed.  
In practice, neither Monte Carlo nor explicit LBTE solution methods are 
exact, and both methods produce errors. In MC, errors are random and result 
from simulating a finite number of particles and following each particle as it 
interacts with a medium. When MC methods employ techniques to accelerate 
solution times or reduce noise, statistic errors are assumed although systematic 
errors may be also introduced whether you abuse of an excessive recycle of 
particles from a phase space file. In the explicit LBTE solution methods, errors 
are primarily systematic and result from discretization of the variables in space, 
angle, and energy. Larger steps in the discretization process result in a faster 
solution, but less accuracy. In both methods, the efficiency is a trade-off between 
speed and accuracy (Vassiliev et al., 2010). Nevertheless, the efficiency is better 
handled with MC by considering as a parameter directly linked to the number of 
events. Differences between the two methods may also result from the treatment 
of charged particle Coulomb interactions.  
Nevertheless, it is important to remark that the MC calculation implemented 
in commercial algorithms is partial, since it does not include in a direct manner 
the simulation of the particle interactions with the linac head, in particular with 
the MLC, which plays a key role in VMAT. The accuracy of most commercial 
algorithms is limited by approximations used in the characterization of the 
radiation beam as well as approximations used to model the coupled electron-
photon transport in complex heterogeneous media (Chetty et al., 2007). For the 
LBTE solutions, it would be extremely complex, and even more inefficient, to 
solve the beam particle interactions with the linac head components, and 
therefore, these algorithms are only used to calculate the dose in the patient 
geometry. 
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1.3 Monte Carlo treatment planning in VMAT - CARMEN MCTP 
As previously addressed, there is a fundamental disagreement between VMAT 
representation in most TPSs and the actual delivery: the discrete calculation of 
a dynamic process. In each TPS, the dynamic operation of the linac is modelled 
based on VMAT specific parameters which describe the mechanical and 
dosimetric limits of the treatment unit into a discrete process. 
The connection between TPS and treatment unit is the DICOM treatment 
prescription, created by the TPS and interpreted by the linac. The standard for 
data transfer from the TPS to the treatment unit or R&V system is the DICOM 
RT plan format. In the DICOM RT plan prescription, a treatment beam 
(conventional, IMRT, or VMAT) is represented with a series of control points 
including the corresponding variables mentioned before, plus a set of properties, 
such as the treatment unit name and beam energy. In the case of static beam 
IMRT, all CPs for a specfic beam have an identical gantry angle, whereas for 
VMAT, all CPs usually have a different gantry angle. During beam delivery, the 
treatment unit will travel along all prescribed values in the CPs in the specified 
order. Therefore, the linac may need to adapt time-related parameters such as 
dose rate, leaf speed or gantry speed, in order to synchronize dose delivery at the 
control points. CP sequences have to be created to achieve a delivered dose 
distribution as close as possible to the calculated one. 
In practice, VMAT treatment delivery is guided by a dedicated control loop 
feedback system. The machine monitors the actual values of all parameters 
many times in the time interval between CPs. One of the varying parameters is 
appointed as leading parameter to which all other parameters must be 
synchronized. This synchronicity will not be perfectly performed, so tolerances 
must be defined stating for each of the parameters to what extent it may deviate 
from ideal synchronicity. 
The treatment unit will try to deliver the VMAT treatment as fast as 
possible, i.e., using that combination of speed and dose rate that will result in 
shortest delivery time. In between CPs, each varying parameter needs a certain 
amount of time to change from one prescribed value to the next. In a VMAT arc 
with a low number of MUs and little leaf motion, the gantry speed is likely to be 
the speed limiting factor. On the other hand, when the number of MUs is high, 
the dose rate is likely to be speed limiting. The actual delivery time of a VMAT 
prescription may differ between treatment machines, since maximum dose rate, 
gantry speed and MLC speed are machine dependent. 
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On Elekta machines, the delivered MU fraction is the leading parameter. 
Every 40 ms, the control system checks that all other dynamic parameters are 
within tolerance, for the actual number of delivered MUs. On Varian machines, 
the control system has been split into two parts: the machine control system and 
the MLC controller. The former monitors the delivered MUs and other 
parameters as a function of the gantry angle, while the latter monitors the MLC 
leaf positions as a function of gantry angle. The leaf positions are checked 
against the prescription every 50 ms for C-series machines and every 10 ms for 
TrueBeam machines (NCS, 2015).  
The trade‐off between complexity and treatment efficiency previously 
presented as the limiting factor inherent to the VMAT technique (Bortfeld and 
Webb, 2009), may not be such a limiting factor in the context of more modern 
linear accelerator design. More recently, new MLC designs have been 
commercially released, which allows for leaf speeds of up to 6.5 cm/s (Bedford et 
al., 2013), and some upgraded control systems (e.g. Elekta Integrity) allowing 
for continuous variable dose rate (CVDR). Investigations have also been made 
into the delivery of VMAT plans using flattening filter‐free linacs (Zhuang et al., 
2013), approaching the > 1000 MU/min, resulting in delivery systems with 
higher efficiency. 
 
The benefit associated with the use of VMAT technique is argued by a higher 
efficiency, introducing new parameters in the planning. This efficiency is based 
on the reduction of radiation treatment times, but the clinical application results 
are very dependent on the planning algorithms used, and also on the linac itself. 
Therefore, treatment planning solutions, based on accurate dose calculation and 
optimization methods able to provide deliverable plans which can be executed 
and verified with more confidence, are desirable to justify the use of VMAT. In 
addition, one should have in mind that this confidence can be provided by 
reliable and accurate verification systems, in accordance to the high accuracy 
used to generate the treatment. This issue will be discussed later. 
In order to objectively evaluate the feasibility and efficiency of VMAT 
technique, where situations of nonstandard radiation fields have a greater role, 
the calculation of the dose should be theoretically carried out, beyond the use of 
analytical algorithms. Full MC (fMC) simulations, in addition to the dose 
calculation based on the physical heterogeneities in the patient, make possible 
to consider MLC transmission, scattering and secondary particles contributions 
in order to take into account the physical characteristics of the beam reaching 
the heterogeneous patient structures (Reynaert et al., 2007). 
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Monte Carlo methods are particularly well suited to calculate the dose from 
the complex MLC apertures commonly proposed during optimization process 
and finally used for the delivery of the VMAT treatments. The fundamental 
challenge of applying fMC as a MCTP system is to enable the consideration of 
all geometries implicated and perform the dose calculation in operating times for 
clinical practice. For VMAT solutions, the sequence of segments may be 
achieved from direct aperture optimization, since it results in more efficient 
solutions maintaining connectivity with the delivery, as aforementioned. As so, 
previous work developed in the Medical Physics group at the University of 
Seville was focused on developing and improving optimization algorithms in 
order to find the most efficient segments and beams in the planning process, to 
be integrated in a full MC treatment planning (CARMEN). As a result, a direct 
aperture-based optimization model applied to VMAT technique, exclusively 
based on patient image data was developed, to allow directly deliverable 
solutions and to perform a full MC dose calculation, resulting in a total 
treatment planning time within clinical routine times  (Ureba et al., 2014).  
The CARMEN MCTP is based on the sequencing of a biophysical map, which 
is generated from enhanced image data of patients to achieve a set of segments 
actually deliverable. In order to reduce the required computation time, the 
conventional fluence map has been replaced by the biophysical map which is 
sequenced to provide direct apertures that will later be weighted by means of an 
optimization algorithm based on linear programming in order to impose 
restrictions at the voxel level (Ureba et al., 2014). 
This approach also enable the incorporation of dose painting by number, since 
the use of multimodality image providing morphological and functional data is 
easily implemented into the planning voxel by voxel. The information of the 
computed tomography (CT) necessary for planning can be complemented by 
magnetic resonance imaging (MRI), or positron, or single-photon emission 
tomography (PET and SPECT, respectively). This leads to even smaller and 
more complex segments, involving much sharper dose gradients from the 
planning target volume (PTV) to nearby OARs. In these conditions, MC 
simulation and an adequate verification, which constitutes part of the work 
presented in this thesis, can have a greater significance. 
CHAPTER 1. INTRODUCTION   
 
16 
1.4 VMAT quality assurance  
Quality assurance (QA) in radiotherapy comprises a series of processes designed 
to ensure consistency of the medical prescription within the clinical tolerance, 
and safe fulfilment of that prescription. Among the main objectives, it is also 
intended to minimize the dose deposited in healthy tissue and exposure of 
personnel, trying to ensure adequate patient monitoring aimed at determining 
the end result of treatment (WHO, 1988). 
Overall, potential errors associated with advanced radiotherapy include dose 
calculation inaccuracies, plan transfer error, beam delivery errors, and target 
localization uncertainties due to patient setup errors and organ motion during 
the treatment. Considering the consequence of these errors, a comprehensive QA 
should be performed before and/or during the patient treatment (Kutcher et al., 
1994). This QA, thus aims the general reduction of uncertainties through the 
whole radiotherapy process, trying also to minimize and correct errors, in order 
to ensure an optimized treatment delivery with maximized tumor control 
probability and minimum injury to normal tissue.  
VMAT commissioning and routine quality assurance builds upon the existing 
IMRT beam models and IMRT QA protocol. However, its completely dynamic 
implementation (combination of dynamic MLC with varying dose rate and 
gantry speed), and new method of operating the linac, demands additional QA 
measurements, as compared with IMRT and requires a rigorous QA program. 
The correct treatment delivery must be ensured by extensive dosimetric 
verifications which include both machine general specific performance and 
verification of treatment plans by measurements of delivered dose distributions. 
Focusing on the context of this work some of these steps are presented in the 
following subsections. 
1.3.1 Commissioning and QA of treatment equipment  
Before implementing VMAT, the acceptance testing and commissioning of the 
various aspects of the planning and delivery system should be performed, for 
which, extensive dosimetric measurements are needed. Periodic QA checks and 
audits can later ensure the maintenance of the original characteristics. Beam 
calibration, or the determination of dose at reference conditions, and its stability 
is a fundamental QA step, where the machine output is required to define the 
monitor unit. This is the charge collected in the machine’s primary dosimetry 
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system, which corresponds to delivery of 1cGy under reference conditions, 
following formalisms specified by international codes of practice, such as IAEA 
report 398 (IAEA, 2001) and AAPM’s Task Group 51 (Almond et al., 1999). 
However, the use of nonstandard fields increases the uncertainty associated to 
the determination of absorbed dose to water and compromises the quality of 
treatment planning. This prompted the creation of a Working Group of reference 
dosimetry on nonstandard fields through the collaboration of IAEA and the 
AAPM, which published recommendations for the development of a new 
dosimetry protocol (Alfonso et al., 2008).  
In the TPS, thorough commissioning of the beam has to be performed in order 
to ensure that TPS calculated dose distributions reproduce the output of the 
treatment machine. The beam model should relate to the geometries in the 
resulting VMAT plans (e.g. small field sizes and elongated field shapes). 
Additionally, a rigorous commissioning of the MLC is extremely important in 
order to obtain an adequate modeling by the current treatment planning 
systems. Appropriate leaf modelling is of great importance since, for a 
considerable part of the planning, only leaves are the beam modifiers blocking 
the radiation field. This effect may be slightly limited if collimator jaws are 
allowed to adapt to the MLC field shape and follow the most retracted leaf. Leaf 
transmission and inter-leaf leakage are often the most challenging part of the 
TPS commissioning. In addition, leaf positional accuracy, leaf-end penumbra 
modeling, the output of small segments defined by the MLC, small MU delivery 
stability, and communication lag between the MLC and linac controllers are 
some of the factors that potentially can significantly alter the prescribed dose. 
Entering the actual physical values in the TPS may nevertheless not always 
guarantee adequate correspondence between TPS and measurement, due to 
limited modelling in the TPS of the dynamic aspects of the treatment.  
It is clear from the previous subsections that VMAT delivery is a complex 
process, requiring the linac to modulate various dynamic components 
simultaneously. As such, there is a strong requirement for routine machine QA 
regimes to ensure that the delivery system is working as expected. Typical 
recommendations on the tests, tolerance values and action levels for linac QA 
are presented in the AAPM Task Group 142 report (Klein et al., 2009). Although 
QA regimes for fixed-field IMRT are already well established in the literature 
(IMRT Collaborative Working, 2001), the additional QA measures required for 
VMAT are not so clear. To date, several publications provide guidance on 
commissioning and QA for what concerns general machine performance by 
addressing issues such as accuracy in MLC positioning during rotation and 
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machine performance at variable dose rate. Ling et al. (2008) suggest tests 
examining the accuracy of MLC leaf positioning (e.g. picket fence pattern 
delivered with rotating gantry), the ability to vary and control dose rate and 
gantry speed for Varian RapidArc. In this study a direct relationship between 
MLC leaf position errors and leaf speed was observed. For Elekta VMAT, tests 
on beam flatness and symmetry, MLC leaf calibration, sliding window dose, as 
well as rotational accuracy were considered necessary (Bedford and Warrington, 
2009). For dynamic MLC QA, log files have been used to detect leaf position 
errors (Agnew et al., 2014; Kerns et al., 2014), since it is assumed that actual 
leaf positions are recorded at a time point during treatment. However, some 
studies, which also used electronic portal imaging device (EPID)  measurements, 
have observed that the leaf positions recorded in the log file cannot be 
considered to be the actual leaf positions during the delivery without an 
independent experimental verification for supporting it (Agnew et al., 2014; Neal 
et al., 2016). 
An important aspect for VMAT is that, while the individual components of 
delivery can be checked independently, a set of tests need to be developed for 
checking the synchronization of these components. As mentioned before, during 
delivery time-related parameters such as dose rate, leaf speed or gantry speed, 
may need to be adapted in order to synchronize dose delivery at the control 
points. Therefore it is important that the limitations of these parameters of a 
treatment unit are realistically defined in the TPS (NCS, 2015). 
1.3.2 Patient-specific quality assurance  
The complexity of the IMRT delivery chain justifiably gave rise to a requirement 
of pre-treatment dosimetric QA for each patient plan (patient-specific QA). The 
purpose of patient-specific QA is to ensure that all plan parameters are properly 
transferred from the planning system to the treatment machine and that the 
measured plan closely matches the plan predicted by the treatment planning 
system.  
Since VMAT is a form of IMRT, patient-specific QA is an integral part of the 
clinical practice. Furthermore, as the essential justification of this work, it is 
necessary to emphasize that the planning and delivery of IMAT should be more 
tightly integrated than IMRT due to the additional requirements on the linac 
control, as addressed before.  
Most methods used for patient-specific QA of IMRT have been adapted for 
VMAT QA. These include applying a treatment plan to a phantom to allow the 
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calculated and the measured doses to be compared (Bedford et al., 2009; Haga et 
al., 2009; Letourneau et al., 2009). A common strategy consists of per-beam 
analysis (measurement vs. TPS calculation) in a single plane in a flat phantom. 
This strategy was summarized in detail in the AAPM TG 119 report about the 
IMRT commissioning (Ezzell et al., 2009), and also outlined in the ESTRO 
Booklet No.9 report (Mijnheer and Georg, 2008). However this approach is not so 
suitable for a rotating beam. 
As rotational therapy grows in popularity, new QA strategies are emerging, 
one of which is the use of 3D dosimetry phantoms to allow the entire rotational 
plan to be delivered to the phantom and the corresponding measured dose 
values compared to the TPS calculations on the virtual model of the phantom 
(Bedford et al., 2009; Letourneau et al., 2009). More promising methods may be 
sensitive to important dosimetric inaccuracies, like recreating dose distributions 
using recorded delivery control files (Schreibmann et al., 2009; Teke et al., 2010; 
Tyagi et al., 2012) 
In considering a patient-specific QA solution, it is important to understand 
the performance of the QA device as a measurement system for rotational IMRT 
and know the limit of each system in order to obtain a high-quality VMAT plan 
QA.  
Dosimetric QA systems for VMAT must be robust in measuring radiation 
emanating from any gantry angle. In addition, possible sharper dose gradients 
may require higher detector spatial resolution (smaller detection active volumes 
and more detectors per unit volume) compared to other forms of IMRT delivery. 
Important characteristics of radiation detectors and the majority of detector 
types used for dosimetry, and also implemented in current VMAT QA systems, 
were discussed in a recent review (Seco et al., 2014). 
Most of the current and emerging VMAT dosimetry systems and techniques 
are herein described, and their main advantages and drawbacks are also 
addressed. Among others, the following are highlighted: 
- Film and ionization chamber; 
- 2D diode array (MapCHECK in MapPhan phantom); 
- 2D ion chamber array (MatriXX in MULTICube phantom and PTW 729 in 
Octavius); 
- 3D diode arrays (Delta4 and ArcCHECK); 
- Dose reconstruction (COMPASS, Delta4DVH, 3DVH, DVH4 Verisoft, 
MobiusFx). 
This amount of different options also shows that VMAT verification is not a 
closed issue.  
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1.3.2.1 Two dimensional treatment verification  
Ionization chamber and film dosimetry 
Two dimensional (2D) spatial dose distributions are measured with relative 
dosimetry using passive and active methods, usually combined with one 
absolute dose measurement from which absolute dose values can be obtained 
(Figure 1.3). 
The classical systems include ionization chambers typically used for absolute 
point dose verifications and radiographic or radiochromic films for 2D relative 
dose measurements. The ionization chamber is considered a good detector in 
regions of shallow dose gradients and for measuring low doses. In fact, the 
accuracy of the ionization chamber may be affected during IMRT as there are 
moments that the ionization chamber is outside the field or is partially 
irradiated. The role of volume effect is small compared to the effect of electron 
disequilibrium. The possible impact of this on absolute dosimetry has been 
investigated in terms of Monte Carlo simulation of stopping-power ratios 
(Sanchez-Doblado et al., 2003) and ion chamber perturbation (Capote et al., 
2004). These studies indicated that the measuring error may amount to a 
considerable percent for individual segments, although the overall error could be 
compensated depending on the IMRT plan. 
Film dosimetry can provide 2D dose distributions with high spatial 
resolution. Films are usually placed in water equivalent phantoms at planes of 
interest (Figure 1.3). The relative dose distributions obtained can be scaled to 
absolute values through cross calibration with a small ionization chamber 
measurement. 
 
Radiochromic film is an alternative to radiographic film. The Gafchromic® 
EBT film was specially designed for IMRT QA purposes. It does not have to be 
Figure 1.3. PTW Semiflex 0.125 cm3 and 0.3 cm3 ionization chambers (left) 
(PTW), and films placed in the Easy Cube phantom (right) (DonaldsonMarphil). 
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handled in a dark room thus can be easily cut and loaded under normal room 
lighting conditions. The lack of chemical processing not only reduces the post 
irradiation work load but also removes one of the more problematic aspects of 
traditional film dosimetry. The composition of radiochromic film is much closer 
to water or tissue and thus gives a more representative measure of dose in these 
materials compared with silver bromide radiographic film. A proper procedure 
for using this film as a dosimeter has to be established, because the performance 
also depends on how the film is scanned and analyzed.  
Planar detector arrays 
Different commercial detector arrays appeared through the last decade 
responding to the clinical demands and consisting usually in a number of 
detectors placed at fixed positions in a water equivalent phantom. Most detector 
arrays present a two dimensional, or planar, geometry, like MapCHECK (Sun 
Nuclear Corporation, Melbourne FL), PTW729 (PTW-Freiburg, Germany), or 
MatriXX (IBA Dosimetry, Louvain-La-Neuve, Belgium). These detectors employ 
different combination of detection technology, diode or ionization chamber, and 
spatial sampling. Most of them can perform absolute dosimetry measurements 
through the use of a calibration coefficients, generally measured for the central 
detector, and an array of correction factors that compensate for the inter-
detector response variations through the device (Donetti et al., 2006).  
Planar diode or ion chamber arrays inserted into a solid water phantom are 
commonly used for IMRT and were also employed for VMAT treatment 
verifications (Figure 1.4).  
 
                 (a)                (b)              (c) 
Figure 1.4. Example of different dosimetry systems commonly employed for 2D 
IMRT and VMAT treatment verification: (a) MultiCube phantom with IBA MatriXX 
ion chamber array (Chandraraj et al., 2011); (b) Octavius phantom with PTW729 ion 
chamber array and (c) PTW Octavius 1000SRS liquid-filled ion chamber array (PTW). 
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In general, there are technical concerns over the use of both diode and ion 
chamber arrays for performing QA measurements. The small size (<1mm) and 
high signal of the semiconductor (silicon) diodes are attractive qualities for 
dosimetry arrays designed for IMRT verification measurements, allowing 
complex IMRT planar dose distributions measurements with minimal volume 
averaging effect (Feygelman and Nelms, 2011; Li et al., 2009). However, diodes 
arranged in a matrix exhibit directional dependence of response, which is partly 
due to the intrinsic construction of the detectors, and partly to the way they are 
mounted and arranged in the phantom. The angular dependence consideration 
becomes critical when diode arrays are used to measure dose delivered by 
multiple beam geometries as those involved in VMAT plans. Planar arrays, were 
originally designed for field-by-field static gantry IMRT measurements analysis 
with the beam incidence perpendicular to the measurement plane. When used to 
measure dose distributions generated by VMAT, the angular response variation 
becomes a major concern. Angular dependence as large as 20%, was found for 
the original MapCHECK diode array (Jursinic et al., 2010). This is due to the 
intrinsic properties of the diodes, as well as to the phantom design and to the 
way they are mounted on the circuit boards. Dose rate dependence is also of 
particular concern with VMAT treatments. It was shown that the variation of 
dose response with the dose rate for the same detector can reach up to 2.5% 
(Poppe et al., 2006). 
Diodes also present an energy dependent response (Boggula et al., 2011). The 
silicon itself has the average atomic number, mass absorption coefficient, and 
stopping power different from water. In megavoltage (MV) photon dosimetry, 
this issue manifests itself as field-size and depth dependencies of the response, 
once the relative number of low energy photons in a megavoltage beam increases 
with field size and depth.  
Ion chamber-based detector arrays are known to have insignificant energy 
and dose-rate dependence for MV photon beams, but require a larger sensitive 
volume, once the active volume of an ionization chamber inherently has to be 
substantially larger than that of a semiconductor detector to obtain an 
acceptable signal to noise ratio, and therefore will exhibit a volume averaging 
effect in steep dose gradient regions (Li et al., 2009).  Thus, the effect of volume 
averaging needs to be carefully characterized and considered in the 
interpretation of verification results. Although an angular variation of dose 
response also exists for ion chamber arrays, the magnitude is smaller compared 
with that of MapCHECK diode system. Dose response variations up to 8% 
(Poppe et al., 2006; Van Esch et al., 2007) and 10% (Li et al., 2009) can be found 
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when the photon beam is parallel to the detector plane for PTW Seven29 and for 
MatriXX detector, respectively.  
Although instantaneous data analysis provided by these arrays, when using 
these devices for VMAT patient specific QA, the angular dose response and dose 
rate dependence has to be considered during data collection and corrections are 
mandatory. 
Lately, due to the increased use of smaller field sizes, some 2D detector 
arrays based on liquid-filled ionization chamber technology have been developed 
(Figure 1.4(c)). These provide higher spatial resolution measurements, due to 
smaller detector sizes (e.g. 2.3 mm x 2.3 mm x 0.5 mm), and minimal energy 
dependence, although ion recombination effects should be specially considered 
(Knill et al., 2016). 
1.3.2.2 Three dimensional treatment verification  
Even the best planar dosimeter suffers a substantial drawback when used with 
multiple gantry angles or arcs. The amount of modulation information collected 
by the device is dependent on the beam incidence angle.  
Ideally, a 3D dose measurement method would be the most comprehensive 
test, however, currently there is no such 3D measurement technique that can 
meet the requirements of both spatial resolution and accuracy. A gel dosimeter 
and an accurate tomography technique may be a solution but gel dosimeters are 
not routinely used due to the big number of practical issues.  
Several QA strategies have been later developed for VMAT verification 
purposes, including 3D arrays, designed with their detectors distributed in 
several planes. 
The use of film dosimetry in a 3D spatial distribution was also proposed 
(Park et al., 2011; Richardson et al., 2003), but the measurements were not 
managed to reconstruct the 3D dose distribution in the patient anatomy. One of 
these proposals consisted in a novel QA system, based on a cylindrical phantom 
with rolled-up radiochromic films (Park et al., 2011), as an alternative tool to 
detect the pitfalls of planar dose verification and to detect dose discrepancies 
along the arc trajectory. Nonetheless, a 3D distribution from the dose actually 
delivered on rolled-up films was not included, which can be considered for the 
reconstruction of dose-volume histograms (DVHs) in order to allow direct 
comparison with the TPS calculations on the patients’ anatomy. 
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3D detector arrays and phantom-less systems 
Some systems include the use of diode arrays with different geometries, capable 
to provide 3D dose verifications, such as Delta4 (Scandidos, Uppsala, Sweden) 
(Bedford et al., 2009), or ArcCHECK (Sun Nuclear Corporation) (Letourneau et 
al., 2009; Fakir et al., 2012) (Figure 1.5). Delta4 phantom includes a biplanar 
diode array, where the dose is recorded in two orthogonal planes of point 
detectors with an “X” axial cross section, a 3D dose distribution can be 
reconstructed for comparison with the QA plan. The 3D dosimetry system 
ArcCHECK has a cylindrical detector arrangement cross section.  
 
 
The most commonly employed technique for comparing measurements 
obtained with calculations is the gamma comparison which combines distance-
to-agreement (DTA) and percent dose difference (%Diff) into only one parameter, 
called gamma index (Low et al., 1998). However, the gamma index can be 
misleading and insensitive to clinically relevant dosimetric errors. Several 
studies have stated poor correlation between conventional QA and dose errors in 
the patient anatomy (Nelms et al., 2011; Zhen et al., 2011). Therefore, DVH-
based metrics should also be examined, especially in regions with high-dose 
gradients (Song et al., 2015). Apart from singular solutions for own use (Oldham 
et al., 2012), only a limited number of 3D measurement-based anatomy dose QA 
devices are commercially available: 3DVH (Sun Nuclear Corporation), 
COMPASS (IBA Dosimetry) and Delta4DVH Anatomy (ScandiDos). These are 
associated with the previous described diode arrays, capable of provide 3D dose 
verifications, as Delta4 or ArcCHECK, or with planar measurements obtained 
Figure 1.5. Delta 4 detector array (Scandidos, Sweden) at left, and ArcCHECK (Sun 
Nuclear Corporation) at right (Hammond et al., 2011). 
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by an ion chamber array mounted on the gantry, as MatriXX (Figure 1.6) 
(Boggula et al., 2010). Recently, an optional algorithm, called ‘DVH 4D’, can be 
used with the OCTAVIUS 4D version, which allows DVH in patient to be 
calculated. The basic version of OCTAVIUS 4D only reconstructs dose grids in 
the phantom.  
 
 
The Delta4DVH Anatomy and COMPASS use independent dose calculation 
algorithms, which calculate the dose to the patient using the energy fluence. The 
3DVH does not recalculate the dose, but only perturbs the TPS patient planned 
dose to account for known errors measured in the conventional QA (Hauri et al., 
2014). In this case, the limitations related to the dose calculation engine are still 
present.  
The field size dependence of the systems based on detector arrays, limited by 
their spatial resolution, may affect the verification results due to under-
sampling effects (Hussein et al., 2013), and requires careful attention, so DVH-
based metrics should also be examined, especially in regions with high-dose 
gradients (Song et al., 2015). In these cases, a DVH reconstruction based on 
measurements with sparse detection not as dense as the planned dose 
calculation grids requires an interpolation process, which can introduce 
uncertainties. In the best case, this QA approaches could be verifying the dose 
corresponding to a discrete set of CPs proposed by the planning system, but this 
could be not exactly the dose delivered to the patient.  
Figure 1.6. MatriXXEvolution (IBA Dosimetry) mounted on gantry (left) and 
example of the fluence obtained from measurements for a treatment plan 
verification (right) (Boggula et al., 2011). 
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Because of inherent limitations in the measurement resolution, precision, 
energy and angular dependences (Jin et al., 2014; Bedford and Warrington, 
2009), distinct detectors can provide different results for the same treatment 
plan, as it has been reported in several studies (Li et al., 2009; Chandraraj et al., 
2011; Zhu et al., 2013).  
Methods based on detectors mounted on the gantry, or even on the EPID 
already installed on the linac (Woodruff et al., 2015), have the advantage of 
avoiding the angular dependence but they do not provide a direct dose 
measurement, requiring the use of algorithms with different levels of 
approximation to reconstruct the dose in the patient geometry. 
Transmission detectors 
There are other 3D verification methods that not involve direct in-phantom dose 
measurements. These methods vary in their level of reliance on experimental 
data versus dose calculations. 
Some transmission detectors can be mounted on the gantry to monitor fluence 
entering the patient. The measured 2D fluence is then used to recalculate the 
dose distribution on the patient CT dataset by the associated software. Two 
transmission detectors were described: the DAVID multi-wire ionization 
chamber array (PTW, Freiburg, Germany) consisting of a flat, vented multi-wire 
transmission-type ionization chamber, and COMPASS (IBA Dosimetry, 
Germany), which is a transmission 2D array detector of air-vented plane 
parallel chambers. For the latter, photon beam attenuation and secondary 
electron production were reported (Venkataraman et al., 2009). 
Electronic portal imaging dosimetry 
Another alternative is based on the EPID which detect the radiation 
transmitted through the patient and treatment couch. While the devices 
described above are placed upstream of the isocenter, an EPID naturally records 
the fluence measurements downstream (patient exit fluence). 
With the introduction of the amorphous-silicon detectors, the interest in 
EPID dosimetry has been increased due to the favorable characteristics such as 
fast image acquisition, high resolution, digital format, and potential for in vivo 
measurements. Measurements at different gantry angles are easily 
accomplished.  Portal dosimetry can provide an easy and robust way for patient 
specific QA. However its use for quantitative dosimetry is currently a challenge. 
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Different configurations of using the EPID are possible (Iori et al., 2010; 
Mans et al., 2010). The fluence can be acquired without a patient and the dose 
can be reconstructed to mimic a flat phantom dataset or may also be estimated 
via EPID and used to independently calculate on the patient CT dataset. 
Alternatively, output EPID images can be acquired with the patient/phantom in 
the beam and the corresponding dose again can be estimated on the patient. 
Linac log files 
Linac log files (e.g. MLC DynaLog files in Varian RapidArc) registered during 
the irradiation can be considered to compute the delivered dose distribution on 
the patient CT images (Schreibmann et al., 2009; Teke et al., 2010; Tyagi et al., 
2012). It is assumed that the actual delivery process is truly represented in the 
log files, in which the MLC leaf and jaws positions, fractional MUs, and gantry 
angle are recorded. In fact, it is essential to know what has actually being 
performed by the linac at the time of treatment delivery.  
Patient-specific QA has been implemented using logged leaf positions to 
perform safety checks (Agnew et al., 2012), and recently commercial vendors 
have released log-file based patient QA products (MobiusFX, Mobius Medical, 
TX; Compass QuickCheck, IBA Dosimetry, Germany). Nevertheless, its 
implementation as a patient-specific QA method is controversial. Some authors 
point that the major disadvantage of this method is that log files need to be 
validated against an independent system (Manikandan et al., 2012; Neal et al., 
2016). Moreover, some systems do not directly provide this information, as in 
Elekta linacs, forcing the access through the linac controller tools, such as 
service graphing module, not available in treatment mode (Pasler et al., 2015). 
Thereby, these studies are scarce for Elekta systems, facing to better known 
works for Varian systems.   
1.5 VMAT uncertainties – definition of the problem 
It has been shown that VMAT can actually provide demanding dose 
distributions in short irradiation times and fewer monitor units. Nonetheless, it 
is clear these possibilities came in exchange for a high increase in treatment 
complexity that can compromise treatment delivery. The completely dynamic 
implementation involves an added complexity to the planning, and rise new 
concerns about the continuous delivery requiring more extensive QA, to ensure 
its consistency with the planned discrete calculation. Therefore, new QA 
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systems are continuously becoming available, while also there exist no clear 
guidelines and criteria for the accuracy required. The understanding of the 
different uncertainty sources and their relative dosimetric impacts is 
fundamental to design and established comprehensive QA procedures, to 
effectively ensure patient safety and accuracy. 
It could be stated that, unlike static field IMRT, all systems implemented for 
VMAT QA have to face two main sources of uncertainty: one related to the dose 
calculation accuracy common to any modulated technique, and other linked to 
the continuous delivery of a discrete calculation.  
 
On one hand, the dose calculation accuracy is a double problem concerning 
the consideration of patient heterogeneities and also the beam modifiers 
contribution to the final dose. MC particle transport simulation is recognized for 
its higher accuracy to model linac heads, especially in non-standard dosimetric 
conditions, like the ones involved in VMAT treatments. In particular, MC 
method can accurately model small radiation field apertures potentially present, 
not only in the solution proposed by the TPS after the optimization process, but 
also as typical control points from the discretization process of the log files. In 
this way, it is possible to know the final dose contribution of the scattered and 
transmitted radiation through the beam modifiers which, as expected, are 
playing a relevant role in a dynamic modulated technique, such as VMAT. Still 
considering the challenge of achieving operating times for clinical practice, the 
explicit and accurate calculation provided by MC method is suitable for 
assessing the real VMAT capabilities. With increasing complexity in treatment 
planning, posed by this modulated intensity techniques, and also biological 
optimization and evaluation, the knowledge of the low dose levels to organs at 
risk becomes more important, as well as the heterogeneous density 
considerations in dose calculation for lung SBRT techniques. In these situations, 
inaccuracies (e.g. fluence underestimation in the head scatter), in TPS dose 
model could be of significance. 
 
On the other hand, the accuracy of the dose distribution can also be 
compromised by potential differences between the discrete apertures and 
corresponding MUs proposed by the TPS, and those continuously delivered by 
the linac. As discussed throughout this introduction chapter, detailed knowledge 
of plan deliverability is not necessarily available in conventional planning 
systems or secondary dose calculations used for verification. In spite of some 
TPS correctly model the dynamic behavior, even using Monte Carlo dose 
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calculation as Monaco®, most planning systems make an approximation by 
summing doses calculated at the discrete CP and not in between (Manikandan 
et al., 2012). This means that the MUs optimized for a fixed aperture shape are 
actually delivered with different shapes at different angles (Yu and Tang, 2011). 
For this reason, the linac log files registered during the irradiation are usually 
considered to compute the delivered dose distribution. The considerable data 
recorded in log file requires a reduction of the actual dynamic event for the 
subsequent calculation. This reduction imposes a level of discretization that can 
be equivalent to the considered in the planning system (Schreibmann et al., 
2009; Tyagi et al., 2012) but it seems reasonable to think the larger the number 
of CPs calculated from the log file, the better this approximation is. This issue 
was also studied in this thesis. 
In order to cover both type of uncertainties commented above, some works 
proposed MC simulation of log files recorded during treatment delivery (Asuni et 
al., 2013; Boylan et al., 2013; Teke et al., 2010). The dose distribution 
discrepancy introduced between the discretized plan and the continuous delivery 
was assessed by incorporating DynaLog files into MC simulations for RapidArc 
QA (Teke et al., 2010). For that work, a new DOSXYZnrc source (Lobo and 
Popescu, 2010) was used to compute the dose distribution, by considering a 
continuous variable beam configuration, through sampling-based methods. This 
approach reached simulation times for routine clinical applications, although 
the required statistical uncertainty was only ensured in the high dose voxels. It 
could be efficient for treatment verification but not suitable to assess one of the 
expected VMAT benefits associated to the decrease of low dose radiation to 
surrounding normal tissue. Furthermore, this approach may over-simplify 
VMAT delivery in certain parts of the arc where changes in gantry speed are 
larger than in others and the variable dose rate could not be considered with the 
same accuracy. This could be important to assess the potential radiobiological 
influence of different dose rates during VMAT delivery. Because of these 
considerations, other works incorporate different methods to represent the linac 
motion with a VMAT delivery emulator (Boylan et al., 2013) where important 
differences were found between static and continuous dose calculation, as it was 
differently reported by Teke et al. (2010). It is important to remark that 
different results could be also linked to the type of verification systems 
implemented to assess the impact of VMAT delivery efficiency, since dose 
experimental measurements should be used to support the dose calculation from 
log files, or even from an emulator. Actually, these approaches showed only an 
accurate second check of dose calculation based on MC by considering the 
CHAPTER 1. INTRODUCTION   
 
30 
delivered geometrical parameters, since no experimental measurements were 
directly included to estimate the actual dose dynamically delivered to the 
patient. For this purpose, the discretization degree and the accuracy used in 
dose calculation would be sensible to the efficiency of detectors and their 
locations inside VMAT systems.  
For an accurate 3D VMAT verification with high calculation resolution, based 
on the information provided by the log file, it would also be desirable the 
implementation of an experimental validation with high resolution detection in 
order to minimize the potential mismatching. Although the data analysis 
process makes film dosimetry a less popular method for QA compared to 
previously mentioned verification systems, the high spatial resolution, minor 
energy dependence, and near tissue-equivalence provided by the radiochromic 
films, are well suited for VMAT QA purposes.  
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1.6 Hypothesis and Objectives 
Hypothesis  
The high accuracy provided by the MC explicit radiation transport simulation, 
and the high spatial resolution from film dosimetry can control and potentially 
reduce the uncertainties involved in complex dynamic techniques, such as 
VMAT, and are suitable to complete the required commissioning and develop 
adequate QA strategies. 
 
Objectives 
1. Monte Carlo modelling of linac heads and characterization of the 6 MV 
photon beam used for VMAT treatments. 
 
2. VMAT verification by means of an automated Monte Carlo simulation of TPS 
plan parameters. 
 
3. Implementation of Monte Carlo simulation of log files under a flexible 
sampling model in order to consider the dynamic irradiation by using the 
actual parameters recorded during the treatment delivery.  
 
4. Design of a specific phantom to allow 3D radiochromic film measurements, 
and experimental support to be integrated in a MC-based QA model. 
 
5. Development of specific software to process and implement the dosimetric 
measurements from the phantom into the MC simulation in order to provide 
experimentally reconstructed DVHs.  
 
6. Application of the proposed model to clinical cases in order to test the 
operational feasibility to address potential limitations in VMAT optimization 
algorithms and commercial verification systems. 
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Chapter 2 
Materials and Methods 
 
The interplay of the many variables being used over a broad range of 
magnitudes in VMAT optimization and delivery, implies demanding QA 
methods. During the introduction chapter different methods and systems have 
been mentioned and described for that purposes, which present different level of 
robustness. It was also pointed out that solutions where errors in QA can be 
meaningfully correlated to patient specific geometry and structures, using 
measurements to recalculate DVHs can detect clinically relevant dose errors 
better than the widely used gamma criteria. Solutions to reconstruct the dose in 
the patient anatomy have therefore been integrated in commercial available 
systems, which are based on measurements in a phantom or others, which can 
use some type of ‘phantom-less’ measurement to reconstruct the 3D dose in the 
patient anatomy. Although these software systems claim the capability to 
estimate patient dose based on QA measurement, the confidence on using such 
products to perform patient DVH-based QA requires further investigation, as 
already pointed by some authors (Zhen et al., 2011), in the case of IMRT QA. For 
VMAT QA this could be even more important, since the approximation level 
used in these software to estimate the continuous delivery can introduce 
discrepancies and the result can also be compromised by detection density 
implemented in the 3D dose reconstruction.  
For the work developed in this thesis, two commercial systems, one based on 
phantom and the other on phantom-less measurements, were used for the 
verification of clinical VMAT treatments, in order to evaluate them and to 
compare with MC verifications and, finally, to check with the QA model 
developed as part of this thesis. Therefore, a technical description of these 
commercial QA systems is included in a first section, for further discussion. 
Since we support the hypothesis that a highly accurate QA system suitable for 
the complexity of such technique require the most accurate calculation provided 
by MC, the second section will describe the application of MC simulation carried 
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out for this work, as a tool for routine VMAT treatment verification. 
Furthermore, some related experimental support carried out with basic film 
dosimetry and also employing these commercial devices is outlined. In the third 
section of this chapter, the proposed self-developed model to complete the MC 
based QA with experimental measurements for an effective VMAT evaluation 
will be described. 
2.1 Commercial systems used for VMAT treatment verification  
COMPASS and Delta4 systems were used for verification of VMAT treatment 
plans at Hospital Universitario Virgen del Rocío (HUVR) and Hospital Infanta 
Luisa (HIL) in Seville, respectively. The implemented COMPASS at HUVR is 
commonly used to verify VMAT plans previously calculated by the Philips 
Pinnacle TPS and delivered with an Elekta Synergy linac. On the other side, the 
Delta4 system implemented at HIL is used to verify Monaco TPS solutions 
delivered with an Elekta Axesse linac. 
2.1.1 COMPASS QA system 
The COMPASS QA system (IBA Dosimetry) consists of a software package (also 
called COMPASS) for dose calculation as well as visualization and analysis of 
measured data that is acquired using a gantry-mounted MatriXXEvolution detector 
array and a gantry angle sensor. 
MatriXXEvolution, which is an upgraded version of I’mRT MatriXX, has been 
developed for composite dose verification of rotational techniques such as VMAT 
and consists of 1020 vented pixel ionization chambers arranged in an active area 
of 24.4 cm × 24.4 cm with a pixel-to-pixel distance of 7.62 mm arranged in a 32 × 
32 matrix (there are no chambers in the corners of the array). Each ion chamber 
has a volume of 0.08 cm3, a diameter of 4.5 mm and 5 mm height. 
The purpose of the dose computation in COMPASS is to provide an 
independent dose calculation engine in order to cross-check the dose calculated 
by the TPS. The dose engine (including a beam model of the linac head) 
implemented in the COMPASS software uses a collapsed cone 
convolution/superposition algorithm for calculating the 3D dose distribution. 
Dose calculation is a two-step procedure: first, the TERMA (total energy 
released per unit mass) distribution is calculated; second, this energy (TERMA) 
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is convolved with the energy deposition point kernels in directions which 
represent the whole surrounding cone in space. 
The beam data required for the beam model in COMPASS is equivalent to the 
one required in the TPS, and usually the data from TPS commissioning can be 
used (profiles, depth dose curves, output factors, absolute calibration). In 
addition, the detector commissioning is also a necessary step when using 
COMPASS, in order to incorporate the detector model. 
2.1.1.1 Fluence acquisition and COMPASS dose reconstruction 
Before the patient-specific dose verification can be carried out, the patient plan 
data have to be exported from the TPS to the COMPASS software. For each 
treatment, COMPASS requires four data sets, all exported via DICOM (Digital 
Imaging and Communications in Medicine): the RT Plan, the RT Structures, the 
dose calculated by the TPS (RT dose) and planning CT images. To perform the 
measurements, MatriXXEvolution is inserted in a dedicated holder and mounted 
directly on the gantry. In this configuration, the dose is delivered with original 
gantry angles identical to the patient plan. The delivered fluence measurements 
of the treatment plan acquired with the MatriXXEvolution are recorded together 
with the measured gantry angle, by the external gantry angle sensor, directly in 
the COMPASS software. The sampling time for the measurements taken for the 
evaluated cases was set to 300 ms. COMPASS workflow is represented by the 
schematic diagram in Figure 2.1.   
Primarily, COMPASS determines the fluence for all segments in a beam. As 
this quantity cannot be directly measured, COMPASS does first a calculation of 
the expected response (electrical signal) for each segment and detector pixel, 
based on linac and detector models (previously commissioned). This is called the 
predicted or expected response. After the measurement, the predicted and 
measured responses are compared. The residual response (response difference) 
is then used for a computation of the really delivered fluence, considered in the 
final dose reconstruction. Therefore, the algorithm implemented in COMPASS 
uses a combination of ‘ideal’ and measured fluences to determine the ’real’ 
delivered fluence. 
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Figure 2.2 shows the comparison between the expected response in the 
MatriXXEvolution detector (computed from RT plan DICOM file) and the 
measurement taken for a CP of one of the studied cases. Besides small 
deviations notably distributed in the edges of the CP irradiated area, it is 
important to note the limited spatial resolution in the measurement.  
The spatial response function of a pixel is wider than its physical dimensions 
and the response function is regarded as isotropic. During COMPASS dose 
reconstruction, the effective resolution is increased from 1 cm to 2 mm by a fit 
procedure, where the coefficients of a series of 2D fluence functions are adapted 
to best fit the response measurements (Boggula et al., 2010).  
Once the whole treatment plan is delivered, the dose is reconstructed on the 
CT images from the delivered fluence (indirectly measured dose). The purpose of 
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Figure 2.1. Schematic diagram of COMPASS workflow for 3D treatment verification 
and patient dose reconstruction from MatriXXEvolution detector mounted on gantry for 
full 360° fluence acquisition. DICOM files are imported from the TPS in the 
COMPASS software, and the 3D dose is reconstructed using fluences derived from 
MatriXXEvolution measurements with the patient’s planning CT data. A comparison 
between DVHs calculated using TPS data and COMPASS dose reconstructed is 
finally carried out. Adapted from (IBA; Vikraman et al., 2014). 
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the dose reconstruction is to provide some information about the actual dose 
that is being delivered to the patient. In general, the reconstructed dose from 
the delivered fluences would help to detect any delivery errors which could go 
unnoticed in a regular treatment process. The dose distributions and DVHs 
reconstructed from the fluence measurements are then compared with the TPS 
calculated plan, as shown in the Figure 2.1. These reconstructed 3D dose 
matrices and the respective measured frames were extracted from COMPASS, 
for further analysis and comparison with MC simulated fluences and MC dose 
verification of the cases evaluated in this work. 
 
 
 
2.1.2 Delta4 QA system 
The Delta4 QA system (ScandiDos) comprises a cylindrical phantom made of 
PMMA with the dimensions of 22 cm in diameter and a length of 40 cm, and the 
associated software. Inside the phantom there are two detector planes crossing 
each other in the isocenter (Figure 2.3, bottom left). The two detector planes 
consist of 1069 p-type Si diodes. The detection area per plane is 20x20 cm2, and 
the diodes are disc shaped with a volume of 0.04 mm3, placed with a spacing of 
0.5 cm in the central area (6x6 cm2) and a spacing of 1 cm in the outer area. An 
inclinometer attached to the accelerator gantry and connected to the Delta4 
Measured response Predicted response 
Difference response 
Figure 2.2. Expected detector response in the MatriXXEvolution array for a CP, 
computed in COMPASS (upper left) vs measured detector response (upper right); 
difference histogram and matrix difference (bottom left and right), respectively. 
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system gives the continuous independent information about the gantry angle 
during the arc delivery. 
For each measurement, the Delta4 system is able to sort the dose 
information into sub-beam-structures, corresponding to the control points of the 
plan from the TPS. The sorting is made by associating the measured dose from 
each dose pulse from the accelerator with the actual gantry angle at the dose 
pulse delivery, measured by the inclinometer. The dose pulses measured during 
the gantry angle interval of a control point are summed together, giving the dose 
corresponding to that CP. The Delta4 phantom is calibrated to absolute dose 
measurement using a farmer reference ion chamber for the specific linac, and 
can thus be used to measure absolute dose level. 
In its basic implementation, the one currently used at HIL, the measured 
dose at the detector positions is compared to the planned (recalculated on the 
CT-image of the Delta4 phantom in Monaco TPS), and a gamma analysis is used 
to verify the correspondence between dose distributions (Figure 2.3). For a more 
comprehensive evaluation, a 3D dose reconstruction on the phantom can also be 
made. For each plan CP, the rays are traced through the measurement points, 
and the TPS dose calculated on the Delta4 phantom along each ray is 
normalized to fit the measurement.  
  
Figure 2.3. Gamma analysis in Delta4 for the axial slice corresponding to the 
isocenter, for the evaluated H&N case also verified with the model proposed in this 
work, including axial films. 
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2.1.2.1 Delta4 DVH Anatomy 
The recently (April, 2016) version of Delta4, among other upgraded functions, 
contains the Delta4 DVH Anatomy 2 option, which allows the 3D patient dose 
reconstruction. In this option the incident fluence can be approximated from the 
phantom measurement and used for dose calculation on the patient dataset with 
a pencil beam algorithm or with the treatment plan dose including measured 
modification (TMM algorithm). 
In order to implement this tool to obtain and compare the resulting DVHs for 
some of the evaluated cases, the Delta4 software of HIL was upgraded and 
installed in a PC with a 2.7GHz Intel Pentium CPU (G630) and 8 GB RAM, 
running a 64 bits Windows 7 operative system, at the University of Seville. The 
Delta4 DVH Anatomy license was specifically provided by ScandiDos for this 
work, under a collaboration agreement. This option required a commissioning 
process, similar to the one mentioned for COMPASS system. In this case, the 
head geometry including primary and secondary collimators was first described 
in Delta4 software, to generate the model of the Elekta Axesse linac. The 
required beam characterization for 6MV modality was done by importing 
DICOM RT dose distributions for open quadratic fields, calculated in a large 
water cube with 2mm x 2mm grid and a MC-Monaco uncertainty of 1%. The 
lateral (inline and crossline) dose profiles and percentage depth dose curves 
(PDDs) were then extracted in the Delta4 software, the output factors in air and 
water and absolute dose calibration data were also introduced, and a Gaussian 
source kernel was chosen for the beam characterization process. Beam 
characterization results, showing PDDs and profiles at different depths obtained 
for two of the used field sizes are represented in Figure 2.4. 
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2.2 Monte Carlo simulation for VMAT QA  
Monte Carlo method is a powerful tool to assess the details of the energy 
deposition process that accounts for all aspects of primary and secondary 
radiation transport inside the treatment machine head, and also within the 
patient. MC simulation has been already implemented as a tool for VMAT QA 
and treatment verification. In order to model the passage of a particle through, 
for example, a slab of tungsten, a particle detector, or even the human body, the 
ability to link the outcomes of successive interactions and particle trajectories 
forming the particle shower is required. The EGS (Electron Gamma Shower) 
code (Nelson et al., 1985), developed at the Stanford Linear Accelerator Center 
Figure 2.4. Screenshots of Delta4 DVH Anatomy software showing beam 
characterization results. PDDs and some dose profiles for 2.4 x 2.4 cm2 and 10.4 x 
10.4 cm2  fields. TPS (· ) and Delta4 characterization ( - ). 
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(SLAC), represents an unification of particle interactions for the coupled 
simulation of electrons and photons in an arbitrary material geometry from a 
few keV up to several hundred GeV. Using EGS, quantities of interest can be 
calculated by averaging over a given set of MC particle cases or histories. 
The Monte Carlo code used throughout this work was the simulation package 
of the coupled electron-photon transport EGSnrc (Kawrakow, 2000a; Kawrakow 
and Rogers, 2000) developed by the National Research Council of Canada 
(NRCC). The EGSnrc is an extended and improved version of the EGS4 package 
originally developed at SLAC.  
 
The BEAMnrc (Rogers et al., 2011) and the DOSXYZnrc (Walters et al., 2009) 
are widely EGSnrc-based Monte Carlo simulation user codes for simulating 
radiotherapy beams and calculating dose distributions in phantoms or in 
patients, which were developed as part of the OMEGA (Ottawa Madison 
Electron Gamma Algorithm) project to simulate the dose delivered by typical 
energy beams in radiotherapy. The former was designed to simulate radiation 
beams from any radiotherapy source, including Co-60 and even low energy x-
rays and the latter was designed for calculating dose distributions in rectilinear 
voxel geometry. Both codes were already implemented for the MC simulation of 
the radiation transport through all the elements involved in the VMAT 
treatment, i.e. the linac treatment head, the phantoms employed in the 
dosimetric measurements and finally the patient, and their geometry (Lobo and 
Popescu, 2010). 
2.2.1 Linac head modelling 
An accurate model of the clinical linear accelerator used for VMAT delivery is an 
essential step during the all simulation process. In this step, the geometry of the 
linac treatment head of the Elekta Synergy installed at HUVR (Figure 2.5) was 
modelled using BEAMnrc (Rogers et al., 2011) for a nominal energy of 6MV, 
based on the technical specifications regarding the dimensions, geometrical 
configuration and material composition,  which were provided by Elekta, under 
a non-disclosure agreement. A schematic overview of the Elekta Synergy linac 
head is depicted in Figure 2.6.  
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The Elekta Synergy accelerator is equipped with the MLCi2-type multileaf 
collimator (Figure 2.5), consisting of 40 leaf pairs with rounded ends and a 
projected width at the isocenter (at 100 cm from the source) of 1 cm, allowing a 
maximum field size of 40 x 40 cm2. Once the leaves are separated from their 
neighbors by a small nominal gap to minimize friction and there is no tongue 
and groove or interlocking steps in the leaves of the MLCi2 (in contrast with the 
previous model MLCi), the interleaf leakage is reduced by a slight leaf bank tilt 
of the focused leaves. The MLCi2 leaves have the ability of interdigitation, if 
enabled by the linac control system, an over travel distance of 12.5 cm and a 
maximum leaf speed of 2cm/sec. 
The MLC with 8.2 cm thick leaves is complemented with secondary 
collimators (see Figure 2.6), which consist of a 3.0 cm thick X backup jaws fitted 
below the MLC to minimize the radiation leakage and perpendicular to these, a 
7.8 cm thick Y jaws for full attenuation, all made with a tungsten alloy.  
To produce a photon beam, an electron beam impinges on a tungsten target 
giving rise to bremsstrahlung photons; the beam is collimated by the primary 
collimator and flattened by the flattening and difference filter, depending on the 
energy; the ionization chamber is used to monitor the output of the linac and the 
backscatter plate protects the chamber from backscatter photons; the mirror 
(not presented in Figure 2.6) projects a light field on the patient and allows 
visualization of the collimator settings. The MLC is a combination of a set of 
thin collimating leaves which can be positioned individually, in this way an 
Figure 2.5. Elekta Synergy accelerator installed at Duques del Infantado, Hospital 
Universitario Virgen del Rocío (left) and its MLCi2 multileaf collimator model 
(right). MLC images from (Elekta). 
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arbitrary field shape can be generated. The jaws are collimator blocks that can 
be positioned to limit the leakage and transmission through the MLC. At the 
exit of the linac head, the beam passes through a mylar screen, which has lines 
printed on it to indicate the isocenter position. 
 
 
The accelerator head geometry was built using a number of individual 
component modules (CMs) present in BEAMnrc that are perpendicular to the 
beam axis, which are specifically designed and optimized to model different 
geometries for different components in the treatment head. It is possible to 
modify the physical dimensions and material of the CM, in order to match the 
specific components according to the manufacturer’s specification. The CMs used 
to model the Elekta Synergy treatment head were: FLATFILT for target and 
flattening filter, CONESTAK for primary collimator, CHAMBER for ion monitor 
chamber, MIRROR for mirror, MLCE for MLC, VARMLC for X backup jaws, 
JAWS for Y jaws and SLABS for the backscatter plate, the mylar screen and for 
the air gap between the exit mylar and the desired phase-space plane. A 
representation of the accelerator head modeled in BEAMnrc with all the CMs 
can be seen in Figure 2.7.  
Figure 2.6. Schematic representation of the Elekta Synergy linac head for the 6 MV 
photon beam operating mode (property of Elekta limited). 
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Although all the information was supplied by the manufacturer, the access of 
some detailed specification was limited, mainly in what concerns the detailed 
geometry of the MLCi2 leaf. Some physical parameters, specified in the 
BEAMnrc component model MLCE (Figure 2.8) used for modelling the MLCi2 
geometry were, therefore, completed by theoretical geometric considerations. 
This CM model was mostly coded by Nick Reynaert at the University of Ghent. 
To account for the beam divergence and minimize the geometric penumbra 
across the leaves, the leaf sides are focused towards the target, which means 
there is a difference in width between the leaf top side and bottom side for all 
the leaves to line up with the beam divergence. To define the top and bottom 
Figure 2.7. XZ-plane representation of the Elekta Synergy linac head geometry (6 
MV modality), with the different component modules in the BEAMnrc user code. 
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thickness of the leaf, the projected width at the isocenter was rescaled by ray-
tracing, taking into account the interleaf air gap to the Z distances of each 
defined thickness. 
On the other hand, the rounded leaf end design of the MLC leaves and 
backup jaws (with parallel leaf motion), leads to a nonlinear relationship 
between the physical leaf opening and the projection at the isocenter plane. As a 
result, the actual positions were calculated by applying a correction algorithm 
(2.1), through trigonometric relationships, for the rounded tips, taking into 
account the corresponding radius of curvature. In any case, the leaf offset 
corrections provided by the manufacturer to account for the rounded leaf tip 
were similar to the corrections being applied with this correction algorithm. 
 
𝑥𝑓 =
{
 
 
𝑥0
𝑧0
𝑧𝑓 + 𝑟√1 +
𝑥0
2
𝑧0
2  , leaf in its MLC bank.  
𝑥0
𝑧0
𝑧𝑓 − 𝑟√1 +
𝑥0
2
𝑧0
2  , leaf over central axis.
 ,                 (2.1) 
where, 𝑥0 and 𝑥f are the initial and final positions, respectively, being 𝑧0 the 
source-to-isocenter distance, and 𝑧𝑓 the source-to-leaf defined radius distance, 
and 𝑟 the radius of curvature. 
Figure 2.8. Schematic representation of the MLCE CM (Rogers et al., 2011), showing 
its geometry and the input parameters required in BEAMnrc user code for this module. 
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Moreover, this CM model allows the entire leaf bank rotation in a plane 
perpendicular to the leaf opening direction by a specified angle (in radians), to 
consider the previously mentioned leaf bank tilt. This slight rotation is set by 
the manufacturer to reduce the leakage transmission between the leaves in the 
MLC. As shown in Figure 2.7, this linac model has two pairs of jaws below the 
MLC, thus the necessary tilt can be small. 
The interleaf gap was also adjusted from the recorded particle tracing of their 
transport simulation through the MLCE. During a BEAMnrc simulation, 
particle positions can be recorded when they cross air-leaf or leaf-air boundaries 
through this CM used to model the MLC, following the method developed by 
Heath et al. (Heath and Seuntjens, 2003). A representation of the MLC model 
implemented, recorded during this simulation in order to adjust the interleaf 
gap is shown in Figure 2.9. 
 
 
A number of scoring planes can be applied at the back plane of any CM in the 
modelled accelerator, where a phase-space data (PSD) file can be scored. The 
PSD is the most important output from BEAMnrc where information of each 
particle’s complete history, energy, position, incident angle and charge is stored. 
The PSD file can also be used as an input file for further Monte Carlo dose 
calculations, e.g. the photon beam incident at the surface of a phantom with 
DOSXYZnrc.  
For the BEAMnrc simulation, apart from the input file establishing the 
parameters that control the radiation transport and specify the geometry and 
the materials in the linac head, the cross-section data for the media composing 
the CMs is required. This information is contained in a pegs4 data file 
(*.pegs4dat file) previously generated from the composition of the different 
Figure 2.9. Cross-sectional views of the 40-leaf MLCi2 model generated by particles 
tracing recorded during BEAMnrc/EGSnrc simulation. (a) MLC end view, (b) zoom of 
the MLC end view, and (c) leaf side view.  
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materials and their densities. The same is done for DOSXYZnrc regarding the 
media represented in the patient CT. 
2.2.2 Source modelling and beam characterization   
Accurate dose calculations require an accurate Monte Carlo model, which means 
that not only correct information about the accelerator head but also about the 
incident electron beam is needed.  
The actual shape and spectrum of the primary electron beam source incident 
on the target to generate the photon beam are rarely known. Even the same 
accelerator model presents different spectra for the same nominal energy for 
each installation. Therefore, it is necessary to deduct this spectrum from reliable 
experimental dosimetric measurements (PDDs and lateral dose profiles), which 
characterize the beam. In this case, the 6 MV photon beam from the Elekta 
Synergy linac was modelled.  
To simulate the primary electron beam incident on the target an energy 
spectrum with a Gaussian radial intensity distribution was modelled by the 
source routine number 19 in BEAMnrc (Figure 2.10). The radial spatial 
Figure 2.10. Geometry of the BEAMnrc’s ISOURC=19 (Rogers et al., 2011). This is 
an elliptical beam where the ellipse is defined by Gaussian intensity distributions in 
X and Y. The beam can be parallel, with specified direction cosines, or has a mean 
angular spread about the Z-axis. If the σ or FWHM of the Gaussian distribution in 
the Y and X direction are equal, the beam results in a circular beam with a Gaussian 
radial distribution, as it was assumed in this case. 
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intensity was given by the full width at half maximum (FWHM). This value is 
also commonly described by the standard deviation in the Gaussian distribution 
(FWHM =2√2 ln 2𝜎 ≈ 2.35𝜎). 
 
As the initial electron beam leaves the accelerator vacuum and hits the 
bremsstrahlung target, the characterization requires a fine tuning of the 
different parameters for the electron beam in order to match Monte Carlo 
calculated dose distributions within an accepted error (less than 2%) with 
measured dose distributions in well-known standard conditions. 
To estimate the incident electron beam energy and radial intensity 
distribution, BEAMnrc simulations for a set of field sizes (20x20, 10x10, 20x5, 
5x20 and 2x2 cm2) were performed. Different combinations of the mean energy 
and FWHM values, ranging from 6.0–6.5 MeV and 0.75–2.0, respectively, were 
evaluated to find the appropriate values (table 2.1). Due to the tilt presence in 
the MLC, the value of this parameter was also investigated during the 
simulations, what meant a hard task because the results showed to be very 
sensible to this parameter. Simulations with no tilt and with small tilt 
variations were performed, starting from 0.0013 rad which corresponds to a 0.5 
mm displacement over the source focus.  
A phase-space file was scored just below the accelerator head at 54 cm from 
the bremsstrahlung target for each simulation. An initial number of histories 
(from 5x107 to 5x108) were simulated to obtain the necessary number of particles 
recorded in the phase-space files depending on the field size and the required 
statistical uncertainty (less than 1%). 
For the transport parameters, global cut-off energies for electron and photon 
transport, respectively, were set as follows: ECUT (including the electron rest 
mass energy) = 0.7 MeV, similar to AE (threshold energy for electron creation, 
defined in the medium file); PCUT = 0.01 MeV, similar to AP (threshold energy 
for photon creation, defined in the medium file). The boundary crossing 
algorithm EXACT and electron-step algorithm PRESTA-II were used, and for 
Bremsstrahlung and pair angular sampling the complete modified Koch-Motz 
distributions were considered. The National Institute of Standards and 
Technology (NIST) cross section data base was used for the bremsstrahlung 
production. 
To improve the simulations efficiency, variance reduction techniques were 
also employed. In this case, it was used the range rejection with an energy cut-
off of 2.0 MeV and the Directional Bremstrahlung Splitting was also used with 
variable splitting field radius according to field setting.  
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The phase-space files obtained were used as inputs for DOSXYZnrc to 
calculate the dose distributions in a water phantom. The dose distributions were 
compared to the experimental measurements, provided by HUVR, including 
PDDs and lateral dose profiles at several depths (1.5, 5, 10 and 20 cm), 
previously obtained with ionization chamber and semiconductor diode. 
Phantoms with dimensions of 10 x 10 x 36 cm3 for 2 x 2 cm2 field, and of 30 x 
30 x 36 cm3 for the rest of field sizes were constructed with a voxel dimension of 
0.1 x 0.1 x 0.1 cm3 in the first case, and with 0.3 x 0.3 x 0.3 cm3, in the second 
case, to have a better resolution for smaller field sizes. 
For these simulations, particle transport parameters were similar to those 
used for the BEAMnrc simulations, except the energy threshold for electron 
transport, ECUT, which was set to 0.521 MeV. The number of histories required 
in each run to get the desired statistical uncertainty is dependent on the field 
size and the voxel size. Smaller voxels were necessary for the smaller field sizes 
and therefore, a larger number of histories was required to get the desired 
statistical uncertainty. In all cases, the particles in the phase-space file were 
recycled 3 times to obtain less than 1 % of uncertainty in the smallest voxels of 
each simulation. In this way, the recycling considered did not incorporate 
systematic errors 
All MC simulations were distributed on a cluster of four 12-core 2.19 GHz 
CPUs AMD Opteron, in a parallel architecture, installed at the Fisiología 
Médica y Biofísica Department of the University of Seville.  
 
 
Table 2.1. Variable parameters for the different field sizes simulated during the 
calibration process of the 6 MeV energy beam delivered by the Elekta Synergy linac 
installed at HUVR.  
Field size 
(cm2) 
Mean 
energies 
(MeV) 
Radial 
FWHMs (mm) 
Tilt (rad) 
BEAMnrc (N hist.) / 
DOSXYZnrc (N rec.) 
20 x 20 6.0/6.25/6.5 1.5/1.1 0.0013/0.0017 5x107 / 3x 
10 x 10 6.0/6.25/6.5 1.5/1.1 
0.0013/ 
0.0017/0.01 
5x107 / 3x 
2 x 2 6.0/6.25/6.5 0.75/1.1/1.5/2.0 0.0013/0.0017 5x108 / 3x 
5 x 5 6.0/6.25/6.5 0.75/1.1/1.5/2.0 0.0013/0.0017 5x108 / 3x 
5 x 20 6.0 1.5 0.0013/0.0017 5x107 / 3x 
20 x 5 6.0 1.5 0.0013/0.0017 5x107 / 3x 
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2.2.3 MC verification of VMAT TPS calculation   
The 6 MV photon beam from the Elekta Synergy modelled in this work, and also 
the 6 MV photon beam from the Elekta Axesse linac model validated in other 
work (Ureba, 2015) were used to simulate several clinical cases from both 
hospitals, HUVR and HIL. 
Different treatment locations with distinct complexity, including SBRT lung 
and radiosurgery (RC) cases, head and neck (H&N), prostate, and other 
locations, all solved with VMAT technique were included for evaluation. These 
cases were previously planned with commercial TPS Pinnacle V9.0, or Monaco 
V2.3, and verified with the aforementioned commercial systems, IBA 
COMPASS/MatriXX, or Delta4. 
For the MC simulations of all VMAT treatments, a PSD file was first 
obtained from the simulation of the treatment-independent components in the 
linac head, in order to be used as source for the transport simulation through 
the geometry of beam modifiers specific to each case. This enables a considerable 
reduction of the global simulation time. The subsequent PSD files, were then 
obtained for each one of the simulated control point geometry, and scored at the 
exit of the linac head.  
The BEAMnrc transport parameters were analogous to the ones used for the 
MC beam calibration process. Conversely, there was no need for DBS to improve 
efficiency, since the PSD file corresponding to the simulation of treatment-
independent components was used as the main source for subsequent 
simulations of the CPs. 
In order to implement a routine VMAT verification by means of an automated 
MC simulation system, an in-house program was developed for the automatic 
explicit simulation of the geometry of every CP, through the acquisition of the 
data contained in the RTP files from MOSAIQ system. The general workflow of 
this automated process is represented in Figure 2.11. The RTP file contains the 
parameters for the linac to deliver the treatment (gantry angle, MLC and jaw 
positions, and MU for each CP, mainly). However, it has a specific format and 
particular characteristics for VMAT, and thus differs from the previously known 
LANTIS structure and IMRT plans, widely used in our group. To overcome the 
communication problems encountered with this different RTP file format, its 
structure has been studied and new records were identified, which are described 
in the next subsection. This allowed the creation of a program written in shell 
(Linux) to automatically extract all the required plan parameters and 
automatically create the input files for the BEAMnrc user code. 
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Similarly, DICOM-RT plan ﬁles exported from the TPS can also be used for 
simulation, so this automated process was then adapted to MATLAB, in order be 
integrated in the CARMEN platform. CARMEN is a specific MATLAB-based 
platform developed by the Medical Physics group (Baeza et al., 2015) with a 
graphical user interface (GUI) for a friendly use, which is also used in this work 
for the evaluation and comparison of results. 
The corresponding dose calculation was carried out from the phase-space files 
previously obtained for each CP, by means of BEAMDOSE, a DOSXYZnrc code 
modification already implemented by this research group for a previous work 
(Salguero Castaño, 2008). This code allows knowing every aperture contribution 
or beamlet, in each voxel in order to score the individual dose through each voxel 
of the phantom representing either a patient CT or a QA phantom. In this way, 
the dose distribution can to be weighted by changing the MUs corresponding to 
each individual beamlet. 
The voxelized phantom is obtained from the conversion of the CT numbers, or 
Hounsfield units (HU) to the correspondent physical density, and assigned 
material, according to the respective calibration curve obtained from the CT 
scan, which was used for generating the CT image involved in the simulations 
(see Figure 2.12). Dose calculation was performed with a high resolution grid, 
consisting on 256 × 256 voxels per slice, for a fair comparison with film, when 
applied. For particle transport simulation in the phantom, ECUT was chosen 
considering the voxel size and the electron range for the involved tissues. 
Figure 2.11. Workflow of the automated MC verification process. 
CHAPTER 2. MATERIALS AND METHODS 
52 
 
The number of initial particles was selected according to the number of 
simulated CPs to ensure the statistical uncertainty below 1% in the final dose 
for all the voxels inside the treatment region. This number ranged from 2 to 
4x106 particles per CP. When required, particles in the phase-space files were 
recycled and/or particle splitting techniques were implemented to improve 
statistics efficiently. A typical single arc case involving around 90 CPs took less 
than 3h, using the cluster previously mentioned, and simulating 2x106/CP. 
A conversion factor from MC dose (Gy/history) to Gy/MU has been calculated 
for each linac model, following the formalism by Ma. et al (Ma et al., 2004). The 
number of histories for MU conversion factor is determined by relating the 
absolute dose measured under reference calibration conditions (central axis, 
depth of dose maximum in water, 10x10 cm2 field defined at 100 cm SSD) to MC 
dose obtained from the simulation of the same reference conditions. The 
conversion factors obtained for Axesse and Synergy linac models were, 
respectively, 8.76x1013 and 1.12x1014 hist/MU. 
MC solution of each case was evaluated and compared in CARMEN platform, 
together with the solutions given by the TPS and the commercial dosimetric 
verification system employed. Dose distributions were compared through isodose 
curves and DVHs, as well as difference matrix and gamma function analysis.  
2.2.3.1 MOSAIQ system and RTP file structure 
MOSAIQ is an Elekta’s dedicated oncology information system (OIS), which 
simplify the entire therapy workflow, from initial diagnosis and staging, through 
planning, treatment and subsequent follow-up.  
Figure 2.12. Calibration curve used to generate the MC phantom of a patient CT 
from the HUVR (left) and a representative slice of the converted patient CT phantom, 
showing the 4 different materials being considered (right). 
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At HUVR and HIL a MOSAIQ OIS is the implement platform that works as a 
communication network between the TPS and the Elekta linac, involving data 
integration supported by communication protocols as DICOM.  
As it has been commented before, it is possible to export a set of DICOM files 
containing the patient plan data through the TPS. These are: 
- DICOM CT files, containing the patient’s CT scans.  
- DICOM RT Structures file, including structures and volumes of 
interest (planning volumes). 
- DICOM RT dose file that presents all the distribution characteristics of 
the dose calculated by the TPS. 
- DICOM RT Plan file comprises all the treatment plan information of 
the TPS (e.g. Beams and Dose References). 
When the created plan is sent to MOSAIQ from the TPS, to be then delivered 
by the linac, the DICOM RT Plan file is previously received by IMPAC DICOM 
Communication Module (DCM) product operation and is translated into 
RTPConnect Import file intended to be imported by the MOSAIQ application. 
MOSAIQ performs the importation process that extracts information from the 
RTPConnect Import file and stores the information in the Information 
Management System database. This format is defined as the link between the 
TPS and linac control system, and also can be used to verify and /or correct the 
treatment plan. 
The recorded structure of these RTP files follows the hierarchy presented in 
the diagram of Figure 2.13. The records of the data file, which correspond to the 
structure, illustrated in the following figure present a specific format. Each one 
is identified by its KEYWORD and data elements appearing in a particular 
order. The last field of each record shall contain a calculated Cyclical 
Redundancy Check (CRC) for that record, which shall be a 16 bit unsigned CRC. 
The main RTP file records used to extract information for the treatment 
simulation in MC were: 
- Plan definition record [PLAN_DEF], containing the treatment plan 
identifiers for the patient, the plan, and the staff member who generated 
the plan.  
- Prescription site record [RX_DEF], containing prescription site and 
treatment technique information. 
- Site setup record [SITE_SETUP_DEF], containing the site setup 
information for the prescription site. 
- Treatment field record [FIELD_DEF], containing treatment field 
information. 
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- Control point record [CONTROL_PT_DEF], containing the geometric and 
monitor unit parameters for large leaf count MLCs (i.e. greater than 50 
leaves/side). 
 
2.2.3.2 Validation of MC simulation with experimental measurements 
The required experimental support was initially carried out with radiochromic 
film (Gafchromic EBT3, International Specialty products Inc.), in order to verify 
the correct MC accelerator model and beam calibration, in a homogeneous solid 
water phantom. Some dosimetric measurements, including irradiation with all 
MLC leafs closed and an E shaped segment were performed to evaluate the intra 
and inter leaf transmission and tilt model. The change of the energy spectrum 
with the central axis distance was also studied, by means of the irradiation of 
central axis and off-axis segments with complex geometry. 
Figure 2.13. Diagram of RTP Import/Export data hierarchy. This specification 
defines a treatment plan (course) with multiple treatment (prescription) sites, and 
multiple treatment fields. From RTPConnect manual (IMPAC, 2012). 
CHAPTER 2. MATERIALS AND METHODS 
55 
Additional experimental verification, with Gafchromic EBT3 film, of complete 
treatments was also included in order to validate the MC simulations of 
complete treatments. Films were placed on the same setup as for 
COMPASS/MatriXX verification and also in a cubic solid water phantom on the 
treatment table. The irradiation of complete clinical cases, solved with MCTP-
CARMEN solution in a homogeneous solid water phantom (Ureba et al., 2014), 
were also included to complete the validation of the MC model of the Axesse 
linac. MC solutions were compared to the solutions given by the TPS and the 
dosimetric verification carried out. The agreement between dose distributions 
was evaluated through dose profiles, and gamma analysis.   
2.2.4 MC verification of VMAT by using log files   
Despite MC verification of TPS exported files, such as RTP or DICOM-RT plan 
files, allows a verification of the TPS dose calculation, the verification of the 
continuous arc delivery of VMAT plans is not considered in this way. Moreover, 
this approach can be dependent on the degree of modulation between CPs in the 
arc, providing greater effect and produce more differences in the dosimetric 
verification of plans with a higher level of modulation. Therefore, log files 
recorded during VMAT treatment plans delivery, were considered in order to 
simulate the actual treatment parameters. This was achieved by means of 
specific software written in C++ developed by Rafael Linares from HIL, within 
our research group. This software allows the communication with the Elekta 
linac in real time, under the iCom Protocol, and is able to record all the CP 
parameters every 0.25s or 1s during beam on or beam off, respectively. This 4 
Hz recording rate is similar to other tools implemented for log file analysis in 
Elekta linacs (Tyagi et al., 2012). 
2.2.4.1 Discretization process of log files for simulation 
As part of a QA model applied to VMAT evaluation, the implementation of log 
files into the automated MC simulation process of every CP geometry, and dose 
calculation described above was also carried out. For that purpose, an in-house 
MATLAB program was developed, allowing the analysis and the discretization 
process required for the MC simulation of these files. A flowchart of log file 
analysis and discretization process for MC simulation is presented in Figure 
2.14. 
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The analysis and comparison of relevant delivery parameters can always be 
made without further reduction of the data recorded in these log files. However, 
the data retrieved for MC simulation and dose calculation from log files are 
dependent on the discretization level required for an optimal approximation to a 
continuous delivery. The discretization level used for log file simulation and its 
effect in the developed QA model, presented in the next section was also 
investigated. The discretization method was designed to take into account the 
relationship between changes in MUs and gantry motion, for a higher sampling 
Figure 2.14. Flowchart of log file discretization process for MC simulation. 
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when more significant changes are present in a specific sector of the arc. In this 
way, the dose rate is intrinsically considered for the sampling process. 
Obviously, this process does not lead to equi-spaced CPs along the arc, such as it 
was considered by others in previous related works. 
For our model, the term ‘fine log’ was used when the delivered parameters for 
MC simulation were considered with more CPs describing the arc than the ones 
usually presented in the DICOM-RT plan file from the TPS. This latter, in turn, 
was identified as ‘coarse log’, i.e. when the considered discretization level from 
the log file was equivalent to one of the DICOM-RT plan file. For the coarse 
discretization level, after excluding CPs where there was no variation in 
cumulative MU, the actual cumulative value at the end of each control point was 
retrieved along with the actual leaf positions and the corresponding gantry 
angle, recorded during that sampling time. In general, the number of simulated 
CPs will be dependent on the original treatment plan and its complexity. In 
particular, this number was about three times higher for the fine approach 
compared to the coarse one, for the plans evaluated in this work. 
2.3 QuAArC model  
The main goal of this work was directly linked to the purpose of developing a QA 
model that could be used more effectively for evaluating the accuracy of the 
associated optimization algorithms, delivery systems, and QA devices. 
To complement the VMAT verification by means of the automated MC 
simulation described so far, an in-house model called QuAArC was developed. 
This QuAArC model consists on a system composed by a specific phantom, 
integrated with MC simulation of VMAT log files in a feedback procedure, in 
order to implement experimental measurements with film to estimate the actual 
treatment delivery. This system and associated methodology, as well as, 
validation process with clinical cases are described in the following subsections. 
2.3.1 QuAArC phantom   
Regarding the volumetric nature of VMAT, a cylindrical shape 
polymethylmethacrylate (PMMA) phantom (physical density 1.19 g/cm³), 
consisting of a set of two concentric cylinders, was specifically designed. It was 
aimed to host radiochromic films rolled at different radial distances from the 
isocenter, for a 3D and continuous dosimetric verification. The detailed 
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description with geometrical schemes of the designed phantom prototype is 
presented in the Appendix I. As it can be seen in Figure 2.15, two different 
radial distances were selected in the phantom. This dual configuration was 
adopted to obtain an experimental estimation of entrance fluence, since the 
outer films are located close to the maximum dose depth in PMMA, while the 
inner hosting allows a 3D dose distribution consideration, as it will be described 
later. In order to ensure the films are correctly placed, the cylinders size was 
thought to be equal to the length of films. Moreover, the phantom has several 
marked reference lines to know the exact film location during the setup 
mounting and positioning on the treatment table with the usual laser system 
(Figure 2.15).  
Other components allow a configuration prepared for axial or coronal films 
and dose point measurements with several types of ion chambers at different 
locations. Besides the PMMA components, it also includes a set of cork cylinders 
and inserts to simulate lung or air-like cavities (Figure 2.15). In order to 
consider the verification of several treatment regions, QuAArC phantom 
comprises two different setups: one with dimensions of 30 cm diameter and 30 
cm length (big setup), and the other with 20 cm diameter and 28 cm length 
(small setup).  
   
Figure 2.15. Different setups of QuAArC phantom prototype. The big (top) and small 
(bottom) setups are depicted with radiochromic films rolled at two different radial 
distances. The small setup at the bottom is an independent interior part of the 
phantom, also present in the big setup at the top. Two bases with screws were 
designed for a fine positioning with the laser system. 
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2.3.2 Data processing in QuAArC  
2.3.2.1 Implementation of experimental measurements and film processing 
For QuAArC verification of actual plans, Gafchromic EBT3 films with 
dimensions of 20.3 x 25.4 cm2 were rolled around the outer cylinder, at 1 cm 
depth (2 films), and the inner cylinder, at 6 cm depth (1 film) in the phantom, 
onwards the outer and inner film scrolls, respectively. Absolute dose 
measurements with a CC04 and a CC13 ion chambers (IBA Dosimetry) placed at 
the isocenter for each treatment in QuAArC phantom were also performed. 
Chamber reading conversion to dose was made following the IAEA TRS-398 
protocol, and then compared to the corresponding absorbed dose to water 
calculated by MC in the PMMA QuAArC phantom. This MC dose to water was 
converted by applying a conversion factor determined through MC calculation of 
the water-to-PMMA stopping-power ratio, considering the Bragg–Gray cavity 
theory.  
The irradiated films were processed following a specific protocol, which 
included the characterization procedure of the scanner-film system, in order to 
minimize the related uncertainties. All films were scanned at least 12h after 
exposure, using an Epson Expression 10000 XL (Seiko Epson Corp.) flatbed 
scanner at a resolution of 75 dpi and a depth of 48-bit RGB, without applying 
any color correction. The films were all scanned in the portrait orientation at the 
center of the scanner to use its optimum part, which was determined through a 
characterization process of the device.  
Optical density to dose conversion was done through calibration curves for 
each batch of radiochromic films. The calibration curve for each batch of EBT3 
and 6MV photon beams was obtained by irradiating sixteen pieces of 5 × 6 cm2 
cut from the same film. The pieces were individually irradiated with a 10 x 10 
cm2 beam in reference conditions, with doses ranging from 0 to 400 cGy, for an 
appropriate characterization of the film response behavior, including more than 
12 points as proposed by Bouchard et al. (Bouchard et al., 2009). Because of film 
scrolls normally would receive lower doses than the films used in typical 
verifications, especially in outer films, it was important to have an exhaustive 
characterization of dose-response curve in the low-dose range. For each 
irradiated film, two reference film cuts (4 x 5 cm2) from the same film, one 
exposed to a known dose and the other unexposed, were used to adjust the dose–
response curve for the conditions applying to that film. For the conversion of the 
film pixel value into dose, a multichannel method was used (Micke et al., 2011), 
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and also corrections for the non-uniformity lateral dose dependence response of 
the scanner were applied to the three channels. Although the same effect in the 
longitudinal scanner direction was also characterized, corrections were not 
applied since it was found to be negligible.  
For this process, the support and suggestions received by the Radiophysics 
Department of the Virgen Macarena Hospital of Seville were invaluable. 
2.3.2.2 Dose processing and evaluation 
In order to process and evaluate the unusual dose distribution in the irradiated 
film scrolls, specific in-house software was also developed in MATLAB, which 
incorporates the analysis of dose distributions, profiles, dose difference maps, 
and 2D/3D gamma index. The cylindrical distribution of the films in the 3D dose 
cubic voxelized matrix (1.25 x 1.25 x 1 mm3) demands a specific recruitment 
process based on interpolations each 0.5º between voxel values taken from the 
nearest neighbors in the three axes.  
In order to take into account the disagreement between different coordinate 
systems, one planar MC matrix was reconstructed for each, inner and outer 
scrolls, from 5 planar matrices generated by shifting the isocenter to ± 1 pixel 
(Figure 2.16).  In this way, it was assumed that the uncertainty location 
between MC scroll and film scroll was ± 1.25 mm, for the considered grid. 
During the comparative analysis between both dose distributions, an efficient 
non-deformable mutual information method was implemented in our software to 
account for small shifts or rotations that could take place during the film 
processing.   
Figure 2.16. Location of the dose recruitment in QuAArC to obtain the MC dose 
scrolls (circle balck lines) and absolute dose (central black dot) (a). Individual CP 
contribution to each voxel in both scroll regions (outer in the middle and inner at the 
right), from each CP dose recruitment to be used for reconstruction purposes (b).  
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2.3.3 3D dose reconstruction   
Different approaches were followed in order to reconstruct the 3D dose from the 
experimental measurements in QuAArC.  
A method was first developed to obtain a fluence estimation for each of the 
simulated CPs, from the identification of entrance radiation contribution in the 
outer film scrolls. This would then be applied to correct the MC simulated 
fluence according to the parameters of log file to match the measurement, by 
establishing a relationship between this fluence approximation and actual 
fluence. As these measurements record all accumulated entrance, lateral, and 
exit CP dose contributions from the opposite CPs, the direct contribution of each 
CP was first extracted from the correspondent MC simulation. Although it is not 
possible to separate dose components resulting from primary or secondary 
particles in the measurements, MC simulated CPs from log file could be used in 
order to separate the direct contribution recorded in the outer film scroll from 
QuAArC irradiation. The procedure used for this approach is illustrated in 
Figure 2.17, showing a single CP direct dose contributions identified in the outer 
film scroll, after excluding other contribution, using the information of the whole 
outer MC scroll and the MC dose for a single CP. However, it can be seen that 
using this approach, a heterogeneous result was obtained for the CP evaluated 
in the film measurement (Figure. 2.17 – bottom of the right panel). This result 
was expected and it is common to other commercial verification systems, as a 
result of manage discretely a continuous phenomenon. In our case, this effect is 
even more evident due to the high resolution provided by the film, what is here 
showing as an important reason to use this detection system instead of other. 
Unlike other verification systems, our model provides an excellent scenario to 
achieve a better consideration of the continuous nature of the VMAT 
application. Besides having the precise calculation provided by MC, the isolated 
contribution of each CP in combination with the high spatial resolution 
measurement of experimental film allowed us to develop a novel model for 
VMAT verification, as it will be explained below. 
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A different approach was therefore considered in our proposed model for the 
final 3D dose reconstruction. The measurements were implemented in a 
feedback process in order to experimentally adjust the MUs from the MC log 
simulation and to finally obtain an experimental reconstructed DVH in the 
patient anatomy. To this end, a least-squares optimization method following the 
expression (2.2) was implemented in our software, taking into account the 
measurements obtained with the rolled films and the absolute point dose in the 
phantom. 
𝑚𝑖𝑛
𝑥
1
2
‖𝐶 ∙ 𝑥 − 𝑑‖2
2 𝑠𝑢𝑐ℎ 𝑡ℎ𝑎𝑡 {
𝐴 ∙ 𝑥 ≤ 𝑏
𝐴𝑒𝑞 ∙ 𝑥 = 𝑏𝑒𝑞
𝑙𝑏 ≤ 𝑥 ≤ 𝑢𝑏
          (2.2) 
 
C is the MC dose matrix containing the individual CP contribution to each 
voxel; x is a MU weight vector, considered as a percentage of MU change from 
either the initial solution calculated from the log file or the final proposed 
Figure 2.17. Procedure used to isolate individual CP entrance dose contribution in 
the outer film scroll (bottom-right). The individual CP dose contribution in the outer 
MC scroll (top-left) is subtracted to the total outer MC scroll (bottom-left), and the 
resulting difference with the outer film scroll (upper-left).  
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solution; d is the matrix composed by the films dose matrices and the isocenter 
absolute dose measured with ion chamber; A and b are the linear inequality 
constraint to establish the tolerance of dose difference between MC dose and 
measurements (considering both, positive and negative differences); Aeq and beq 
are the linear equality constraints, specified as a vector and a scalar, 
respectively, which represent the original MU weight vector from log file, and 
the total treatment MU; lb and ub represent the lower and upper bounds for the 
solution x, allowing the control of the variation level on the MU values from log 
file to match the experimental value. In this process, the global contribution of 
each individual CP to the whole treatment is assessed and adjusted according to 
the measurements. The rolled films provide us measurements of fluence 
estimation (outer film scroll) and relative dose contribution (inner film scroll) of 
the direct entrance, lateral overlapping, and the opposite irradiation for the 
whole arc. The contribution of opposite irradiation present in these film scrolls, 
it is not a handicap because it is considered in a global manner along the 
optimization process. It is important to note that the values lb and ub are 
considered as a percentage of the original MU corresponding to each CP in the 
log file. In this way, it is possible to accept only relative small variations for each 
new MU during the iterations in the optimization process. The latter in addition 
to a minimum tolerance of dose difference, makes possible to obtain 
experimental values as a result of an average of the heterogeneity within the 
irradiated area in the film corresponding just to one CP. In this way, the 
adjustment is mainly performed by using the contribution from lateral 
overlapping, what is directly related to the discretization effect applied to a 
dynamic delivery. The latter can be observed in Figures 2.18 and 2.19, where the 
variations in MU for each CP obtained with our model are evaluated for an 
IMRT case and for a VMAT case. For the static IMRT plan (Figure 2.18), the 
variations in MUs are not significant, showing again, the high agreement 
between our MC simulations and measurements in film. Conversely, for the 
dynamic case, Figure 2.19, the variations in MUs are relatively more relevant 
for each CP, as it was expected. Also, in spite of considering the whole 
comparison between experimental matrices and MC matrices in the same 
process can be observed that the MU changes don’t modify substantially the 
original MU distribution along the arc. Otherwise, the model would be providing 
a different solution, but not one experimentally reconstructed, such as it is the 
aim.   
This approach makes possible the study of the effect of considering several 
discretization levels from the log file simulation, since deviations measurement 
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caused by a mismatching detection location can be overcome thanks to the high 
density detection inherent to film dosimetry. 
 
 
 
 
 
 
 
Figure 2.18. Evaluation of MU adjustment during the optimization process for an 
IMRT plan, showing very small changes from the original MUs, as expected. The 
scatter plot at the top represents the percentage of the resulting change (blue) with 
maximum allowed changes in MUs imposed by the upper and lower established 
limits. MU comparison and absolute difference are shown on the middle and bottom 
histograms, respectively.  
CHAPTER 2. MATERIALS AND METHODS 
65 
 
 
 
 
Figure 2.19. Evaluation of MU adjustment during the optimization process for a 
VMAT plan. The scatter plot at the top represents the percentage of the resulting 
change (blue) with maximum allowed changes in MUs imposed by the upper and lower 
established limits. MU comparison and absolute difference are shown on the middle 
and bottom histograms, respectively.  
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On the other hand, the control of parameters in this feedback process would 
also allow obtaining a new proposal of a treatment plan with larger variations in 
MU values, but still in accordance to the experimental measurements, able to 
provide a final DVH on patient CT clinically acceptable. Although this last 
operative option of our method was considered, it was not evaluated for this 
work. 
 
Finally, before describing the clinical application evaluated in this work, a 
general flowchart describing the proposed model is presented in Figure 2.20.  
 
Figure 2.20. General workflow followed in the proposed model. 
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2.4 QuAArC model validation with clinical cases 
The proposed model was tested by applying it to several clinical cases, from both 
collaborating hospitals, HUVR and HIL, solved with different TPSs, involving 
distinct VMAT algorithms and verified with different commercial systems, in 
each center. 
From HUVR, two clinical cases corresponding to prostate and H&N VMAT 
treatments were additionally verified with QuAArC. Both treatments were 
previously planned with Pinnacle TPS and verified with COMPASS system. 
These VMAT plans consisted of a single arc with 90 equi-spaced CPs treated 
with a hypofractionation scheme (3Gy/fx), for the prostate case, while for the 
H&N case consisted of a double arc with a total of 180 equi-sapced CPs. 
Furthermore, both plans have met the acceptance criterion, which was based on 
the DVHs comparison between TPS and COMPASS solutions, through relevant 
dose metrics. 
QuAArC solutions were then compared to the planned TPS solution on the 
patient CT data, as well as the corresponding QA system solution. 
From HIL, also prostate and H&N treatments were selected. For these cases, 
four treatment plans in total were evaluated, two solutions for each one: one 
which was accepted by the commercial verification system and the other which 
not. For the real clinical application, these cases were planned with Monaco 
commercial TPS and verified with ScandiDos Delta4 system. For both cases, 
during the verification procedure with Delta4, the first treatment plan (plan A), 
did not meet the acceptance criteria, which consisted on more than 95% of the 
evaluated points with a global gamma index < 1, for 2.5% dose difference (DD) 
and 2mm distance to agreement (DTA) criterion and a dose threshold of 20%, in 
the Delta4 detector planes. A second treatment plan (plan B) was proposed for 
both cases, in order to find solutions that meet these acceptance criteria when 
verified with Delta4. In particular, the plan A for both cases, prostate and H&N, 
failed with a passing rate of 91.8% and 76.9%, respectively, while the plan B 
passed with 95.6% and 99.6%, respectively. 
The prostate case was selected for this study due to the high similarity 
between the DVHs presented by Monaco TPS solutions for both plans, A and B, 
which consisted of a single arc VMAT treatment composed by 87 and 78 CPs, 
respectively. On the other hand, the H&N case consisted of a boost phase 
treatment. In this case, a single arc VMAT plan with 93 CPs was the plan A, 
and the second plan proposed (plan B) was a static IMRT technique, which did 
pass the Delta4 QA and was accepted for treatment. This IMRT plan, consisting 
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of 34 segments distributed in 9 incidence angles (ranging from 205º to 180º CW), 
and it was specifically considered as a static example to check the correct 
implementation of our software, since potential discrepancies between MC and 
the film scrolls generated by the discretization process would not be present in 
this scenario. 
The QA results in Delta4, from these two cases were then rescued, in order to 
calculate the corresponding DVHs, by means of the Delta4 anatomy option, later 
implemented for that purpose. The solutions were then compared to QuAArC 
solutions. 
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 Chapter 3 
  Results and Discussion 
 
In this chapter, some relevant results obtained from the work carried out to 
accomplish the objectives established within this thesis are presented and 
discussed.  
3.1 Monte Carlo linac head model and beam characterization  
Monte Carlo dose calculations of the different field sizes were compared with the 
experimental measured data in order to characterize the 6 MV photon beam 
used for the MC verification of VMAT treatments.  
These results were achieved with a statistical uncertainty lower than 1%, and 
an agreement within 2% was obtained between experimental measurements and 
MC calculations.  
Furthermore, some experimental measurements with radiochromic film are 
presented, which were included to validate the Monte Carlo simulation of the 
detailed Synergy linac head geometry, including its MLC. Also, some results 
regarding adjustments of the Axesse linac model, made by means of additional 
measurements of specific segments are presented. 
3.1.1 Central axis depth-dose curves and off-axis ratios 
Despite a description of beam parameters (energy spectrum and radial 
distribution) was provided by the manufacturer, the fine characteristics of the 
electron beam could only be determined by means of a deep comparison with 
empirical measurements. This comparison was done for the multiple values in 
the table 2.1 presented in Materials and Methods chapter, which corresponded 
to a set of interdependent parameters, describing the electron source from the 
waveguide. Considering those values, the incident electron beam on the target 
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found for the best fit had an energy distribution, which was assumed to be 
Gaussian with a mean energy of 6.0 MeV and a FWHM of 0.5 MeV. The electron 
beam radial intensity distribution was also taken as a Gaussian with a FWHM 
of 1.5 mm for the nominal 6 MV photon beam.  
The tilt of the whole MLC bank was also considered during this 
characterization process, using a value of 0.0013 radians. Since profiles 
analyzed during the beam calibration process, using standard fields, were found 
to be insensitive to small tilt changes, it was decided to adjust this parameter 
later by means of experimental measurements with film. The backup jaws 
present in this linac model are also used to minimize the MLC transmission, 
thus this tilt effect was not so evident in this first stage. Figure 3.1 shows the 
agreement achieved between PDDs calculated with MC and the corresponding 
experimental measurements provided by the HUVR for several field sizes. 
 
 
 
Figure 3.1. Measured (blue) and MC calculated (red) PDD curves in water for 20x20, 
10x10, 20x5 and 2x2 cm2 field sizes at 90 cm SSD, normalized to dose maximum. 
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Although the parameters described above showed high agreement with the 
measured depth–dose profiles, additional comparison was made using the same 
parameters to check the experimental lateral dose profiles for standard field 
sizes at different depths. Figures 3.2-3.7 show MC-calculated dose profiles and 
measurements in both, crossplane and inplane directions, in order to check the 
correct simulation of both jaws and MLC. The large number of histories 
simulated to obtain the phase-space files, which have been considered as input 
for dose calculations, ensured the statistical uncertainty below 2% in the regions 
under the open field region. Nevertheless, this uncertainty was less than 1%, 
considering the implemented PSD recycling for dose calculation. For better 
visualization of these results, the error bars were not represented in the 
corresponding figures. 
 
 
 
 
 
Figure 3.2. Measured (black) and MC calculated (red) crossplane dose profiles 
in water for 20x20 cm2 field at 90 cm SSD, and 1.5, 5, 10 and 20 cm depth. 
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Figure 3.3. Measured (black) and MC calculated (red) inplane dose profiles 
in water for 20x20 cm2 field at 90 cm SSD, and 1.5, 5, 10 and 20 cm depth. 
Figure 3.4. Measured (black) and MC calculated (red) crossplane dose profiles 
in water for 10x10 cm2 field at 90 cm SSD, and 1.5, 5, 10 and 20 cm depth. 
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Figure 3.6. Measured (black) and MC calculated (red) crossplane dose profiles 
in water for 5.0x20 cm2 field at 90 cm SSD, and 1.5, 5, 10 and 20 cm depth. 
Figure 3.5. Measured (black) and MC calculated (red) inplane dose profiles 
in water for 10x10 cm2 field at 90 cm SSD, and 1.5, 5, 10 and 20 cm depth. 
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The agreement between the simulated and experimentally measured profiles 
was high, although not so much in the tails outside the open field. In these 
regions, MC statistical uncertainty was slightly higher and the experimental 
results were less reliable. The dosimetry systems employed present some 
limitations in these regions, due to their relative size and even energy 
dependence, in the case of diode. In any case, this lower agreement outside the 
field is consistent with the literature. Moreover, this validation was checked for 
small fields with additional film measurements, as it will be shown later. 
3.1.1 Validation of MC model with experimental measurements 
Smaller field sizes, as the 2x2 cm2 or less, were also evaluated, but were not 
considered for initial MC calibration purpose, since the conventional dosimeters 
employed in their measurements could compromise this calibration. The 
detection resolution for small fields required the use of radiochromic film. 
Usually, the physical dosimetry routinely considered as input data for analytic 
Figure 3.7. Measured (black) and MC calculated (red) inplane dose profiles 
in water for 20x5.0 cm2 field at 90 cm SSD, and 1.5, 5, 10 and 20 cm depth. 
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algorithms implemented in commercial TPS, does not fulfil this requirement, so 
once the beam characterization was achieved, the evaluation of single small 
segments taken from whole real treatment was considered. 
Some of the experimental measurements with radiochromic film carried out 
to validate the implemented MLC models, are presented in the following figures. 
Figure 3.8 shows the comparison between MC calculated dose distribution for an 
E geometry made with 3 open leaves and film measurement, in a solid water 
slab phantom. This pattern allowed the verification of dosimetric characteristics 
regarding inter and intra leaf transmission, tilt, and gap modelling of the 
MLCi2, implemented in the MC Synergy model. From the corresponding gamma 
analysis and the dose profile, also presented in Figure 3.8, it is possible to see 
that the ‘peaks’ and ‘valleys’, created by this E geometry, were very similar in 
both distributions and matched accordingly to what was expected, in the case 
that the correct tilt was being applied. 
 
 
 
 
 
Figure 3.9 shows the comparison between measurement and MC calculated 
dose distributions for a specific segment, selected from a H&N IMRT treatment 
solved with MCTP-CARMEN for the Axesse linac model. From the different tilt 
values evaluated, the result corresponding to the final adjusted tilt is presented 
here. 
 
Figure 3.8. MC and film dose distributions, crossplane profile, and gamma analysis 
corresponding to an E shaped field made with MLCi2 of Synergy linac model. Dose 
distributions are normalized to maximum dose. 
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3.2 Monte Carlo verification of VMAT TPS calculation 
VMAT treatment verification by means of the automatic MC simulation of the 
parameters in the RTP file corresponding to TPS solutions was carried out for 
selected cases from HURV and HIL. 
A prostate bed VMAT treatment from HUVR, planned in Pinnacle with two 
arcs equi-spaced in 4º, is presented in Figure 3.10.  
DVHs obtained from the MC verification were compared to the TPS and 
COMPASS solutions, where some differences in planning target volume and 
organs at risk (PTV and OARs, respectively) were observed. The different 
heterogeneities consideration by both algorithms could be relevant in this case, 
and the consideration of the explicit transport by MC for the complex geometries 
could be contributing to the differences at OARs. Therefore, COMPASS and TPS 
present similar behavior at OARs. Although the measurement considered by 
COMPASS could be approximating better the actual dose delivered to the 
patient, this system still includes similar algorithm approximations as the TPS, 
which would explain these similar results for both solutions. In other words, the 
COMPASS system checks the experimental fluence, but not checks the accuracy 
of the calculation, which analytical procedure is called into question especially 
for structures subject to different density heterogeneities, such as rectum with 
air cavities, or bladder, compromised by the beams crossing the femoral heads. 
In this regard, it is important to remark that for the lesion, where this issue do 
not play an important role, the three solutions showed high agreement. 
Figure 3.9. MC and film dose distributions (normalized to prescription dose), and 
gamma analysis corresponding to an IMRT segment created by Beam Modulator MLC 
of Axesse linac model. 
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The same comparison of the three solutions for other two cases is presented 
in Figures 3.11 and 3.12, where similar differences were found for the OARs. 
Although, also important discrepancies were found in the PTVs. Dose 
distributions and DVHs results for a H&N case corresponding to a Hodgkin 
lymphoma are shown in Figure 3.11 and a lung case treated with SBRT in 
Figure 3.12. The H&N case corresponds to a two arc VMAT treatment plan 
(equi-spaced in 4º), while the SBRT lung treatment was planned with 4 partial 
arcs equi-spaced in 2º, resulting in 101 CPs each. 
Figure 3.10. MC verification of prostate bed VMAT case. Isodose lines comparison 
(top) between MC (thick line) and TPS (thin line) in representative planes (sagittal, 
coronal and axial views), and DVHs comparison (bottom) between MC, TPS and 
COMPASS solutions. 
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 Unlike the previous prostate case, and as mentioned above the targets of the 
H&N case in Figure 3.11 showed some differences between MC verification and 
TPS and COMPASS solution. This could be explained by the usual presence of 
greater density heterogeneities in these treatment locations. 
In the lung case (Figure 3.12), planned to be delivered with SBRT technique, 
more relevant differences were found between the DVHs corresponding to the 
PTV, and internal target volume (ITV). This was expected because the lesion is 
completely surrounded by healthy lung tissue, and the consideration of the 
electronic density by the analytic algorithm (the same can be applied to TPS and 
COMPASS) is less reliable in this scenario than in homogeneous regions like 
Figure 3.11. MC verification of a VMAT H&N case. Isodose lines comparison (top) 
between MC (thick line) and TPS (thin line) in representative planes (sagittal, coronal 
and axial views), and DVHs comparison between MC, TPS and COMPASS solutions. 
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prostate. These specific results confirmed previous works, strongly justifying the 
need to implement fMC in the QA protocol for cases as lung with SBRT (Ojala et 
al., 2014). 
  
Figure 3.12. MC verification of a VMAT lung case. Isodose lines comparison (top) 
between MC (thin line) and TPS (thick line) in representative planes (axial and 
sagittal, views), and DVHs comparison between MC, TPS and COMPASS solutions 
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In general, MC verification (considering the RTP file) of TPS solutions 
showed a tendency to an increased dose in organs at risk (Figure 3.10-12), 
regarding the TPS and COMPASS solutions. These observed differences, as 
commented before, seem to be mainly linked to the different algorithm used for 
dose calculation and the potential discrepancies between the planned solution 
and the actually delivered by the linac. 
 
Similar results were found for MC verification of cases given by HIL with 
Monaco TPS solutions and Delta4 pre-treatment verifications. These results 
were not included here to not overextend this document. Nevertheless, specific 
considerations related to Monaco and Delta4 will be discussed later, with other 
results. 
 
It would be risky to say that the conventional verification systems are wrong 
when they do not agree with MC. For similar reasons, it would not be correct to 
say that our MC model is valid when it is in agreement with the TPS solution, 
as it was erroneously assumed by others (Asuni et al., 2013). In fact, considering 
the results from Figures 3.10-3.12, the similarity between TPS and COMPASS 
solutions would lead us to suspect that our MC verification model was not 
properly developed. Besides, if we would only be confident on our MC model 
when it coincides with TPS, what would be the reason for using MC for VMAT 
verification?  
It seems clear that this kind of evaluation, based on MC verification, which 
was stated as efficient for VMAT in previous works, is not suitable to establish 
the reasons of the differences found between the planning and the 
measurements from commercial verification systems for VMAT, and what is 
more relevant, it is not possible to accurately verify if our planning corresponds 
to the dose distribution that the patient will receive during delivery.  
This MC verification procedure only based on the simulation of parameters 
involved in the RTP file from TPS could be enough for a robust verification of 
static IMRT cases (Leal et al., 2003), but needs to be enhanced, such as outlined 
in the hypothesis of this work, to cover the two VMAT uncertainties stated in 
the Introduction section. Before to present results directly associated to the 
model proposed for covering both uncertainties, some complementary results are 
included below in order to show the feasibility of radiochromic film to 
complement MC simulation, such as it is intended to demonstrate. The 
comparative MC vs. film in Figure 3.9 was positive and it could be used as a 
validation support for our MC model but, for VMAT verification treatment, it is 
CHAPTER 3. RESULTS AND DISCUSSION 
81 
necessary to also check if our software is sorting and automatic managing 
correctly all the CPs for the verification of a whole treatment.  
In order to experimentally test our model, experimental verification with film 
placed in the same setup used for COMPASS/MatriXX measurements were 
performed and compared to MC solution, for the same cases presented above.  
 
 
This comparison showed a high agreement with more than 95% of points 
having a gamma index (3mm/3%) <1. These results are represented in Figure 
3.13 for the previous cases except for the lung case because, being this one a 
SBRT case with 4 arcs, it had gotten saturate the grey in film. These results 
confirmed that our MC model was correctly implemented.  
 
In the Introduction section of this work, two important sources of uncertainty 
in VMAT application were declared: the accuracy of the dose distribution 
calculation and another linked to the continuous delivery of a discrete 
calculation. 
On one hand, it could be argued that the contribution of scattered and 
transmitted radiation, through the beam modifiers to the final dose, is being 
accurately considered by MC while it could be underestimated by TPS and 
COMPASS algorithms. It does not seem a weak argument in light of the Figure 
Figure 3.13. Dose distributions for MC (top left) and EBT3 film (top right) at the 
measured plane (between 2 cm of solid water and MatriXXEvolution detector), dose 
profiles (bottom left) and gamma analysis (bottom right) for the same VMAT prostatic 
bed case (a) and VMAT H&N case (b). 
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3.14, where a qualitative fluence comparison for a representative CP of the 
VMAT prostate bed case is presented. MC simulated fluence is compared to the 
measured frame extracted from COMPASS showing the potential effect to the 
total dose due to secondary radiation not well considered by the detection 
system implemented in COMPASS. The commercial verification system and 
TPS not only share the same inaccurate dose calculation algorithm, but also a 
too simple approximation model of the incident beam corresponding to each CP. 
 
 
It is necessary to remark here how important is the level of spatial resolution 
for experimental detection in this work. Commercial systems used for VMAT 
verification do not reach the resolution provided by the film. In our opinion, for a 
deep discussion about the precision involved in these verification systems, it is 
necessary to establish similar comparison as above, before including the results 
corresponding to the verification of complete actual clinical cases. In this case, a 
gantry-mounted MatriXXEvolution detector array provides COMPASS system 
with the experimental data for checking the dose previously calculated by the 
TPS. From this double comparison between MC vs. film (Figure 3.9) and MC vs. 
COMPASS (Figure 3.14), it is justified the need to include a verification system 
with the adequate resolution to establish a fair experimental correction of the 
explicit MC calculation from log file parameters. This means, the best 
measurement for the experimental comparison of this theoretical calculation, 
which describes the actual delivered irradiation. 
 
Figure 3.14. Spatial fluence distribution of a representative VMAT CP from a 
prostate bed case, obtained from the MC simulation (a) and from COMPASS 
acquisition (b). 
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On the other hand and following the discussion regarding the comparison 
shown in Figure 3.13, despite the high agreement between MC and film for 
complete treatments, one still might wonder about the small differences which 
are slightly higher than expected after seeing the comparison MC vs. film for a 
single CP in Figure 3.9. Although ideally our MC model not present absolutely 
any difference with film in Figure 3.9, it may still appear differences in Figure 
3.13, due to the inherent limitations of a discrete solution to represent a 
continuous irradiation in the film. It is clear that a better MC verification will 
have to simulate the geometry of the log file, not those in the RTP file. Also, the 
geometry corresponding to each CP has an associated intensity by means of a 
MU value. This assignation is just an approximation to the continuous delivery, 
so it seems clear that a greater CP sampling from the log file will provide us a 
more realistic simulation. 
3.2.1 Monte Carlo verification of log files 
As it was already described in the Material and methods chapter, to carry out 
this work, it was necessary to develop software for automatic acquisition of 
parameters recorded by the linac control system during the delivery. An 
algorithm was also designed to make a CP sampling with different level of 
discretization by taking the CPs from log file, non-equi-spaced, but according to 
the density of changes along the arc. Therefore, it could be considered our model 
is based on a variable CP sampling. In Figure 3.15 is presented a comparison of 
treatment parameters from the RTP and log files simulated for one of the 
previous cases. 
Figure 3.15. Comparative analysis of the planned treatment parameters (RTP) and 
those recorded on log file for the same discretization level. 
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As can be seen, by setting the same level of discretization of the RTP file, i.e., 
the same number of CPs for MC simulation of the log file, little differences can 
be found. No major differences in the geometries or positions of the MLC, 
neither in the corresponding MUs. Therefore, it was not expected that the 
corresponding MC solutions for RTP and log file, would have been very different.  
Returning to the discussion about the detection density of verification devices 
for VMAT, the question arises about the benefit provided by experimentally 
verify the treatment plan maintaining the same discretization level used by 
COMPASS system. This kind of verification system is, therefore, designed to 
check the planning software, but not give information of what actually occurs 
during the delivery of the plan under evaluation, i.e., estimate the dose that the 
patient can receive.  
 
To be more ambitious, the verification system has to recalculate a better 
approximation to the continuous delivery by increasing the sampling of 
parameters from log file. But also has to take experimental measurements with 
a detection device with enough spatial resolution for a fair comparison. 
In Figure 3.16 is presented a comparison against film between the two MC 
verifications corresponding to the information in RTP and log files presented in 
Figure 3.15. The differences found by comparison the irradiated film with both 
simulations are equally relevant, so that a high-density detection as film reveals 
that the recalculation of log file may provide little if not done with greater 
sampling than the one in the RTP file.  
Moreover, one cannot predict the final effect on the whole treatment volume, 
just from the analysis in a single plane (or several planes), as in Figure 3.16. A 
drawback of using a high resolution system as film in this situation is to obtain 
a 3D measurement, necessary for the reconstruction of DVH and so properly 
reporting how degenerated is the planning and its clinical transcendence. 
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In view of these results and according to the discussion held, we decided to go 
further in the use of MC simulation for VMAT verification. Once developed an 
automatic verification model based on the log file with a sampling adaptable, the 
challenge was to implement a system able to provide an experimental correction 
to the simulated parameters of log file. The high detection resolution provided 
by film was considered as necessary to evaluate a higher sampling by means of 
the model. Therefore, it was necessary to develop a new phantom able to host 
film for 3D dose reconstruction. An ideal scenario would be having fluence 
measurements, 3D detection and absolute dose for complete experimental 
information about the delivery. Thus, the most accurate dose calculation based 
on MC simulation of the parameters related to the delivered geometries during 
irradiation, would be supplemented by a high resolution detection system for 
providing information on the input beam, as COMPASS, plus 3D dose 
measurements, as Delta4 or ArcCheck. 
Figure 3.16. Comparison of dose distributions from MC RTP verification and MC 
LOG file verification with axial film at the isocenter plane and respective gamma 
analysis for the same VMAT prostatic case in Figure 3.15. 
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3.3 QuAArC Model 
3.3.1 QuAArC phantom and data processing evaluation 
The designed phantom prototype was constructed and implemented for a QA 
applied to VMAT treatments (Figure 3.17). Although it is an intermediate 
result, it was developed as one of the objectives established in this thesis.  
Beyond the aim of this work, this phantom can also be used for commissioning 
and other dosimetric purposes. The measurements performed with this phantom 
were integrated with the QuAArC model, developed for the evaluation of VMAT 
and other QA systems. 
 
 
In order to evaluate the reproducibility of these unusual rolled film 
measurements (film scrolls) in the new phantom, repeated verifications of the 
same VMAT treatment plans were carried out. 
Figure 3.18 shows a comparison between film dose distributions obtained for 
the same VMAT plan, verified in two different days, where the gamma index 
passing rates for a 3%/3mm criterion were greater than 99% for the 3 films, 
constituting the outer film scroll and inner film scroll. 
All the technical specifications necessary for the construction of QuAArC 
phantom are included in the Appendix I. The phantom has been extensively 
used for this work and other experiments within the research group showing a 
high stability, easy handling and accurate positioning in the treatment table.  
 
Figure 3.17. Final PMMA phantom QuAArC with rolled radiochromic EBT3 films 
(left) and PMMA slices for axial films with cork cylinders (right). 
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Regarding the data processing in films, potential effects of considering a 
different discretization level from the log files for MC simulation in treatment 
verification was analyzed by comparison after processing of the film scrolls 
irradiated in the QuAArC phantom (Figure 3.19). These effects can be observed 
in the corresponding DVHs experimentally reconstructed on the patient CT data 
(Figure 3.20(c), (f)) by means of the QuAArC model proposed in Materials and 
Methods (section 2.3). Although in the Figures 3.19 and 3.20, only results for a 
prostate VMAT plan are shown, the following considerations can be extended to 
the other plans evaluated in this work. As expected, the more pronounced 
discrepancies between MC log calculation and film were found for the coarse 
discretization, as it is shown in the left column of Figure 3.19.  
Furthermore, the different level of discretization between coarse and fine also 
had an impact on the procedure for obtaining the dose distribution 
experimentally reconstructed (QuAArC solution) from the measurements in the 
QuAArC phantom, as it can be observed in the right column of Figure 3.19. This 
shows how our model could establish the required level of discretization to 
obtain an adequate VMAT verification based on MC simulation of log files free-
dependent on detection density. It is important to remark that these differences 
would not have been so evident whether a lower density detection implemented 
Figure 3.18. Film dose distributions, dose difference matrices and gamma 
analysis, obtained from two QuAArC verifications of the same VMAT plan 
with rolled films (2 at the outer cylinder and 1 at the inner cylinder). 
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in other VMAT verification systems would have been employed. On the other 
side, the consistency of these results provides confidence on our model. 
 
After experimental adjustment, the more relevant MU changes were found at 
the same arc locations for both discretization levels, showing that the procedure 
described in section 2.3.3 did not work randomly along the whole arc, but the 
algorithm proportioned the bigger changes where the differences between 
theoretical and experimental values were higher. Also, as expected, the global 
change was more uniformly distributed along the arc for the fine (Figure 3.20(d) 
and (e)) than for the coarse discretization (Figure 3.20(a), (b)). This latter 
showed that the MU adjustment was mainly carried out with the lateral 
contribution from the contiguous CPs, what was our goal in order to achieve a 
reconstruction of the accumulated MU in the log file with the information 
continuously registered in the film.  
According to the comparison followed in Figure 3.19 with the rest of 
measurements in the phantom, the finer approach provided a more reliable 
reconstructed DVH solution (Figure 3.20(c), (f)), and was considered as the 
necessary option in QuAArC verification procedure for this case. Although 
Figure 3.19. Effects of considering a different discretization level from the log 
files. Percent dose difference matrices of the inner film scroll versus MC Log (left) 
and versus the corresponding QuAArC solution (right) for coarse discretization 
(top) and fine discretization (bottom), corresponding to a prostate VMAT plan. 
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coarse QuAArC approach provided a similar DVH solution that could have also 
been approved, the same was not observed for the rest of analyzed cases. 
Anyway, the evaluation of a larger number of clinical cases would be necessary 
to prove what level of discretization could be enough for an efficient verification 
procedure in shorter times. With this work, we suggest that this kind of studies 
with verification systems different to the proposed model could be biased due to 
the use of lower detection density and to different spatial distribution. 
3.3.2 QuAArC model implementation and validation with clinical cases 
In this section, the verification by means of the proposal, QuAArC model is 
presented for VMAT plans from HURV, which were approved for clinical 
treatment after verification with COMPASS system. Also the results obtained 
with QuAArC are presented for other cases, from HIL, including approved and 
not approved solutions with Delta4 verification.  
Figure 3.20. Comparative reports between original and experimentally adjusted 
solutions for fine and coarse discretization. Angular MU distributions from the original 
log file MC simulation and the experimentally adjusted with QuAArC (a) and the 
corresponding MU differences for coarse discretization (b). The same for fine 
discretization (d and e). DVHs comparison between Monaco TPS solution, MC log file 
simulation and QuAArC reconstructed solution, for coarse (c) and fine discretization 
(f). All for a prostate VMAT plan. 
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Before, a proof of concept was established to indicate the feasibility of the 
feedback procedure explained in sections 2.3.2 and 2.3.3. Figures 3.21 and 3.22 
show the comparison between film scroll dose distributions and QuAArC scroll 
dose distributions, and corresponding dose difference matrices and gamma 
analysis. 
 
 
 
The respective values are presented in Table 3.1, and also the absolute dose 
values obtained with CC13 ion chamber measurements in QuAArC and obtained 
for MC simulations of fine log discretization (MC LOG) and QuAArC solutions 
after experimental adjustment. 
Figure 3.21. Film and QuAArC dose distributions for the verified prostate VMAT 
plan porvided by HUVR to prove the experimental feedback process. Corresponding 
percent dose differences and gamma analysis are shown for outer and inner scrolls in 
QuAArC phantom. 
Figure 3.22. Film and QuAArC dose distributions for the verified H&N VMAT plan 
provided by HUVR to prove the experimental feedback process. Corresponding 
percent dose differences and gamma analysis are shown for outer and inner scrolls in 
QuAArC phantom. 
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Table 3.1. Summary of absolute doses, percent dose differences and gamma index 
passing rates for HUVR evaluated treatment plans. 
 
 
These positive results gave us confidence to apply QuAArC model to obtain 
the experimental reconstructed DVHs. These QuAArC reconstructed DVHs are 
presented in Figure 3.23, for two cases. 
 
 
 
As observed in Figures 3.21 and 3.22, a high agreement was obtained 
between QuAArC and film dose distribution for both verified treatment plans. 
This is also reflected in the corresponding 3% dose difference and gamma 
passing rates presented in Table 3.1, where overall, QuAArC solution after 
experimental adjustment, showed better results or comparable to MC LOG 
solution after a simple MC simulation, as presented in section 3.2, for all 
relative dose distributions. The color code used to represent the percent dose 
Absolute dose (Gy) 
( % deviation) 
Dose difference 
passing rates (%) (<3%) 
γ-index passing rates (%) 
(2%/2mm) 
Outer scroll Inner scroll Outer scroll Inner scroll 
CC13 MC LOG QuAArC 
MC 
LOG 
QuAArC 
MC 
LOG 
QuAArC 
MC 
LOG 
QuAArC 
MC 
LOG 
QuAArC 
Prostate Case 
3,67 3.56 (-3.00) 3.57 (-2.72) 99.05 99.53 97.55 96.63 96.51 90.53 95.45 96.62 
H&N Case 
2.03 2.13 (4.93) 2.16 (6.40) 77.08 90.78 80.43 94.16 78.64 91.90 82.78 97.84 
Figure 3.23. DVHs comparison between Pinnacle TPS solution and QuAArC 
reconstructed solution of both evaluated plans, prostate VMAT plan (right) and H&N 
VMAT plan (left). 
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difference matrices was set according to the passing rate values presented in 
Table 3.1 (% pixels having a dose difference within 3%). Gamma analysis based 
on 2% DD/2mm DTA criteria was also included. When a 3%/3 mm criterion was 
used for gamma evaluation of QuAArC solution, passing rates were greater than 
97%, for both scroll regions (outer and inner), in both plans. Absolute dose 
values agreed well within the 3% for prostate VMAT plan, while for H&N VMAT 
plan, this result was worse, and it was not improved with QuAArC solution. 
Although this disagreement could result in some absolute dose difference when 
reconstructing the DVH, we considered these results acceptable. For this case, 
the reference point or another point should have been chosen in a location less 
exposed to high dose gradient. This measurement should be repeated for further 
evaluation, but the high agreement with film and improved results for QuAArC 
compared to the MC LOG were considered to be sufficiently acceptable to obtain 
a reconstructed DVH, which better estimates the delivered dose. 
 
It is important to note here that the evaluated cases were approved in clinical 
practice after experimental verification carried out with the COMPASS system 
used at the HUVR. In this sense, the solutions provided by QuAArC were 
consistent. However, it was necessary to evaluate the behavior of QuAArC 
system in cases where a conventional check would not have approved the plans. 
 
To cover this scenario, as a part of the proof of concept of the model, 
comparisons of outer and inner film scroll dose distributions with the ones 
obtained by means of QuAArC system were carried out (Figures 3.24 and 3.25), 
for prostate case and H&N case from HIL, respectively. As it was described in 
section 2.4, two solutions were previously planned with commercial TPS 
(Monaco, Elekta) and verified with ScandiDos Delta4 system, for each case: one 
solution failing (plan A) and other passing (plan B) the Delta4 acceptance 
criteria in the clinical application. 
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Figure 3.24. Film and QuAArC dose distributions for the prostate case provided by 
HIL to prove the experimental feedback process. Corresponding percent dose 
differences and gamma analysis are shown for outer and inner scrolls for VMAT Plan 
A (first and second rows, respectively), and the same for VMAT Plan B (third and 
fourth rows). 
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Figure 3.25. Film and QuAArC dose distributions for the H&N case provided by HIL 
to prove the experimental feedback process. Corresponding percent dose differences 
and gamma analysis are shown for outer and inner scrolls of VMAT Plan A (first and 
second rows, respectively), and the same for IMRT Plan B (third and fourth rows). 
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All QuAArC scrolls showed a high agreement with the measured film scrolls 
for both, percent dose differences and gamma analysis, which values are given 
in Table 3.2. Since there is always a limitation regarding the discrete 
calculation, even with the fine discretization under consideration, minor 
differences were assumed. Anyway, these small differences observed were 
mostly located outside the treatment field or at the edges. Note that this 
comparison was carried out with the MC scrolls resolution (1 x 0.7854 mm2 for 
outer scroll and 1 x 0.3523 mm2 for inner scroll) obtained after the dose 
recruitment described in Material and Method section.  
 
Table 3.2. Summary of absolute doses, percent dose differences and gamma index 
passing rates for HIL evaluated treatment plans. 
  
 
As in Table 3.1, Table 3.2 shows a summary of passing rates for dose 
differences within 3% and global gamma index with 2%/2 mm criteria obtained 
for MC LOG and the corresponding QuAArC. The values for the absolute 
dosimetry performed with ion chamber in QuAArC phantom and the obtained 
from MC LOG and QuAArC solutions, were also included in Table 3.2. All MC 
LOG and QuAArC absolute dose values were obtained with less than 1.25% of 
statistical uncertainty, and agreed with the experimental measurement within 
2%. In general, the passing rates improved for QuAArC solution after 
experimental adjustment regarding the MC LOG in both, 3% dose difference and 
gamma analysis. For QuAArC solution, all evaluated plans had a γ index < 1 
passing rate greater than 90% using 2%/2 mm criteria in both scroll regions 
(outer and inner). For 3%/3 mm criteria, passing rates were greater than 98%, in 
all cases. As expected, this same test based on coarse discretization approach 
provided worse passing rates. 
Plan 
Absolute dose (Gy) 
( % deviation) 
Dose difference 
passing rates (%) (<3%) 
γ-index passing rates (%) 
(2%/2mm) 
Outer scroll Inner scroll Outer scroll Inner scroll 
 
CC04 MC LOG QuAArC 
MC 
LOG 
QuAArC 
MC 
LOG 
QuAArC 
MC 
LOG 
QuAArC 
MC 
LOG 
QuAArC 
Prostate Case 
A 2.48 2.51 (1.21) 2.53 (2.02) 92.95 91.94 78.33 84.85 90.77 90.12 87.91 93.19 
B 2.45 2.42 (-1.22) 2.45 (0.00) 92.78 95.48 80.83 91.19 88.34 92.66 89.94 97.09 
H&N Case 
A 2.02 2.01 (-0.49) 2.06 (1.98) 96.89 97.61 89.52 96.04 96.28 97.45 91.19 98.18 
B 2.06 2.07 (0.48) 2.07 (0.48) 97.53 98.16 93.16 94.51 97.87 98.40 96.84 97.60 
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For the IMRT H&N plan B (last row in Table 3.2), the results were practically 
the same for MC LOG and QuAArC solution, meaning that our model did not 
modify the MUs when the delivery was static. It is important to remark that 
this agreement for the static IMRT case was also observed in the DVHs 
comparison with Monaco TPS solution (Figure 3.26(d)), since Monaco calculation 
is strongly based on MC, what is similar to our full MC model. The minor 
discrepancies in OARs could be due to the different consideration of beam 
modifiers contribution to the dose.  
In the static plan, the MC log simulation represented the measurement well 
enough, but it was not the same for VMAT plans, as it can be seen in Table 3.2. 
MU adjustment approach proposed in our system showed to be necessary for 
exhaustive dynamic treatment verification. Apart from the IMRT commented 
above, the VMAT cases which were not accepted with Delta4 verification, were 
well adjusted by our model (plan A in Figures 3.24 and 3.25), although the 
resulting DVHs (Figure 3.26 (a) and (c)) showed to be significantly different to 
the planning with Monaco TPS, while the DVH corresponding to the VMAT plan 
B accepted with Delta4 (Figure 3.26(b)) showed to be very similar to the Monaco 
solution. These results obtained with our model showed to be in tune with 
Delta4 verification. Unlike this, greater differences, especially in OARs, were 
observed with other commercial algorithm, not based on MC, as the one 
implemented in Pinnacle (Figure 3.23). In any case, considering the two 
uncertainties pointed out in the Introduction chapter, it could be estimated that 
the potential discrepancies involved in the continuous delivery of a discrete 
calculation can become more significant than those due to the dose calculation 
accuracy.  
 
Essentially, all the results showed in figures and tables, indicated that the 
model developed was robust and consistent, and were included in this work to 
prove the feasibility of the novel feedback procedure and to provide confidence 
about the experimental reconstruction of DVHs. 
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The comparison between experimental measurements and TPS dose 
distributions recalculated in the QuAArC phantom was also carried out. 
Anyway, the different location of detection points in commercial systems and 
QuAArC phantom, makes inappropriate the direct comparison. In the next 
section, the DVHs provided by the evaluated VMAT verification systems, 
including the recent Delta4 DVH Anatomy option, are presented in order to 
analyze a direct DVH comparison with QuAArC solution.  
 
 
(c) (d)
(a) (b)
Figure 3.26. DVHs comparison between Monaco TPS solution and QuAArC 
reconstructed solution of both evaluated plans, VMAT plan A (a) and B (b), for the 
Prostate case and VMAT plan A (c) and IMRT plan B (d), for the H&N case.  
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3.3.3 Comparison of QuAArC solution and commercial solutions 
DVHs obtained with QuAArC model compared to both solutions provided by the 
evaluated commercial systems are presented, in Figures 3.27 and 3.28, for the 
same treatment plans used for QuAArC model validation. 
When comparing QuAArC and COMPASS solutions (Figure 3.27), very 
similar results to the ones observed in the previous comparison QuAArC versus 
Pinnacle, were obtained. These results could be expected, since both plans have 
been accepted for treatment with COMPASS and this system also use the same 
type of analytic algorithm to reconstruct the dose in the patient anatomy as 
Pinnacle.  
 
 
From the DVHs results of Delta4 Anatomy, using pencil beam algorithm, 
compared to QuAArC solutions, in Figure 3.28, it can be seen that our model 
showed to be consistent for all the plans. Similar results were obtained with 
QuAArC for the plans previously approved with Delta4 (plans B), as expected, 
except small discrepancies that are assumed due to different detection methods 
and reconstruction algorithms. This latter, can be more evident for plans, which 
falied the acceptance criteria with Delta4 (plans A), where this different 
detection density and location, even the distinct approach implemented, could 
introduce more discrepancies in the reconstruction. Therefore, the major 
differences were found for one of the plans A. However in this situations, where 
verified solutions could be different, Delta4 Anatomy can still present the same 
Figure 3.27. DVHs comparison between COMPASS solution and QuAArC 
reconstructed solution of both evaluated plans, prostate VMAT plan (left) and H&N 
VMAT plan (right). 
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result as QuAArC, which means that the final solution is also dependent on the 
degeneration of that treatment plan, regarding the optimization algorithm being 
used, and probably the relative locations of verified CPs and detectors in the 
system.  
 
 
 
Summarizing the evaluation of the clinical implementation, it is important to 
remark that this work was not focused to make a comprehensive study on the 
different verification systems and dose calculation algorithms for dynamic 
techniques. Anyway, few clinical cases were evaluated to check the feasibility of 
our model.  
On one hand, for those cases which were approved with Delta4 and 
COMPASS, QuAArC system provided similar DVHs to the solutions from TPSs 
Figure 3.28. DVHs comparison between Delta4 DVH Anatomy with PB and QuAArC 
solutions for all plans of both evaluated cases. 
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corresponding to planning targets, Monaco and Pinnacle, respectively. More 
important disagreement was observed for DVHs corresponding to OARs in the 
cases from Pinnacle/COMPASS. The dose calculation uncertainty using Monaco 
TPS was observed to be not as relevant as the uncertainty linked to the dynamic 
delivery.  However, greater differences were found when QuAArC solutions were 
compared with Pinnacle TPS, where this uncertainty, linked to the dose 
calculation accuracy, also added discrepancies, as expected.  
On the other hand, for those cases which were not previously approved with 
Delta4 from Monaco TPS solutions, QuAArC did show a greater disagreement 
for DVHs of PTVs. All these results proved that QuAArC system was consistent 
with expected results, what support the viability of the model for this kind of 
studies.  
 
In addition, it is important to note that the QuAArC phantom based on film 
could be implemented apart from MC log calculation, whether the TPS is able to 
provide individualized CP dose contribution. This would lead to more efficient 
computational times for routine pre-treatment verification, although with our 
approach based on fMC calculation, the results were more reliable and, in fact, 
they were ready at time of film processing stage. 
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Chapter 4 
Conclusions 
 
The results achieved in this work allow us to drawn the following conclusions: 
 
1. The model developed in this work allows the VMAT evaluation with high 
accuracy provided by the MC explicit radiation transport simulation of the 
actual delivery treatment parameters from the log files, and with the high 
spatial resolution provided by film dosimetry. 
  
2. The stated uncertainties inherent to complex dynamic techniques can be 
controlled and reduced with the proposed model, what will be useful for 
further studies about VMAT efficiency in specific clinical cases and for the 
evaluation of other QA systems.  
  
3. The detection density level and its location in a specific phantom have to be 
adequately considered to obtain a more reliable DVH. This could be useful to 
detect potential wrong decisions based on the results from commercial VMAT 
verification systems, due to mismatching between control points used for dose 
reconstruction and the detector locations.  
 
4. The specific phantom designed for the implementation of the model together 
with the software developed for data processing have shown to be robust and 
efficient to be considered as a pre-treatment VMAT verification alternative 
for clinical practice. 
 
 
 
  
CHAPTER 4. CONCLUSIONS 
102 
 
  
 103 
APPENDIX I 
This appendix contains the description and geometrical schemes of the designed 
prototype of the VMAT phantom (QuAArC), for manufacturing. 
 
 
 
 
 
 
  
VMAT Phantom 
1. Phantom: 
- General Description 
- Possible setups for different applications 
2. List of components 
3. Schemes 
 
 
1. PHANTOM 
  Description and setups  
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Setups:  
The phantom allows two setups, which are adapted in size for the verification of 
treatments in different locations. Both setups support cylinders and slices. 
Phantom setup for smaller treatment fields. 
From now on small setup.  Phantom setup for larger treatment fields. 
From now on big setup.  
Below it is shown, for the two setup types (big and small), the location of the films rolled 
up around the two cylinders, as well as slices and other components. 
1. Phantom 
Description:  
It consists of a set of two concentric 
cylinders of different diameter to roll 
up around one and/or two 
radiochromic films, apart from axial 
slices to interpose films. This set is 
surrounded by two covers, enclosing 
both the cylinders and the slices. In 
addition, it also presents housings for 
inserts with ionization chambers with 
different dimensions. All components 
are manufactured in some type of 
plastic (polystyrene, PMMA) plus other 
replaceable parts in cork. 
1. Phantom 
Closed phantom view 
0.3mm 
thickness 25.40cm Radiochromic film dimensions:   
20.30cm(W) x 25.40cm(L) x 0.03cm(T) 
20.30cm 
   APPENDIX I 
 
105 
 
  
Setups – rolled up films option (scrolls)  
Big Setup with 3 rolled up films  
Small Setup 
with 3 rolled up 
films 
Inserts and films slightly 
extracted for their visualization 
0.3mm 
Thickness 
20.30cm 
2
5
.4
0
cm
 
Films 
Setups – axial films option:  
To place axial films in both 
setups (big and small), the two 
concentric plastic cylinders from 
previous figures are replaced by 
slices. Additionally, two cork 
cylinders are included at the 
ends (outside the region of 
interest). 
Big setup with slices 
to place axial films 
Small setup with slices to place axial films  
Inserts and small cylinder slightly 
extracted for their visualization 
The covers (external and 
internal) encompass the two 
setups and are closed with front 
and back lids. 
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Big setup with cylinders to place an ionization chamber 
in the center 
Small Setup with cylinders 
Big Setup with slices and cork cylinders inside 
Setups – other images: 
 
 
2. LIST OF COMPONENTS 
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• 2  Covers (external and internal): 
        - 4 hemi-covers (CE1, CE2 ; CI1, CI2)  
• 1 Plastic Cylinder G (big):                     2 Cork Cylinders G:  
        - 2 hemi-cylinders (G1, G2)               - 4 hemi-cylinders (G11, G12 ; G21, G22)   
• 1 Plastic Cylinder P (small):                 2 Cork Cylinders P:  
        - 2 hemi-cylinders (P1, P2)                - 4 hemi-cylinders (P11, P12 ; P21, P22)  
• 13 Slices: R1-9 of 1cm; R10,11 of 0.5 cm; R12,13 of 2.5cm. 
• 30 Screws:  
         - For the lids: 16 of 3.5cm and diam. 0.8cm and 8 of 3.5cm and diam. 0.6cm;  
         - For the supports: 6 of 3cm and diam. 1cm (planar surface head of 3cm of diam., 
which act like legs). 
• 4 Lids: front (TE1, TI1) ; back (TE2, TI2). 
• 2 Supports (S1, S2): 2 plinth + 4 bases.  
• 18 Inserts (prisms): I1,2 of 20.3cm (1 of them is cut); I3,4 of 2.5cm; I5-8 of 5cm in cork 
(2 of them are cut), for phantom filling; I9-11 of 15cm for chambers together with I12-
18: 1x7.8cm + 2x5cm + 2x1cm + 1x0.5cm + 1x0.3cm. 
 
 
  
2. List of components 
2. List of components 
External and Internal 
Inserts 
Supports 
Covers 
External and Internal 
Lids  
Cylinders P Cylinders 
G 
Slices 
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3. Schemes  
Schemes and description of each component from the list  
External Cover (C
E1
, C
E2
) 
• Hollow cylinder with 30cm of outer diameter, 20cm of inner diameter and 28cm 
length, which is cut longitudinally in the central XZ plane, forming 2 symmetrical parts 
(hemi-covers C
E1
 & C
E2
) with tongue and groove between them. Both hemi-covers 
remain closed with the external lids, involving the other components. Big setup. 
 
• References for localization/positioning: Besides the cover’s longitudinal cut that 
serves as lateral references, it also presents two marked references, one longitudinal 
on the top and one axial at its center. 
20,00cm 
CE2 
C
E1
 
C
E2
 
CE1 
Longitudinal reference 
Axial reference 
Cover’s cut 
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• The hemi-covers fit in four points (tongue and groove), what will keep them joined 
providing more stability to the big setup. The hemi-cover C
E1
 has four cylindrical 
junction points of 1.0cm of diameter and 0.5cm thick that fit into the four holes of 
equal dimensions (0.5cm of depth and 1.0cm in diameter) present in the hemi-cover 
C
E2
. 
External Cover (C
E1
, C
E2
) 
CE1 
CE2 
2,00cm 
5,00cm 
CE1 
CE2 
20,00cm 
Schemes of the external cover 
APPENDIX I 
110 
 
  
• Hollow cylinder with 20cm of outer diameter, 18cm of inner diameter and 26cm 
length, which is cut longitudinally in the central XZ plane, forming 2 hemi-covers (C
I1
 
& C
I2
). It works as a structure to fix the cylinders and slices of the phantom, along 
with the internal lids. Small setup. 
• References for localization/positioning: Besides the cover’s longitudinal cut that 
serves as lateral references it also presents two marked references, one longitudinal 
on the top and one axial at its center. 
Internal cover (C
I1
, C
I2
) 
C
I1
 
CI2 CI1 
CI2 
Axial reference 
Cover’s cut 
Longitudinal reference 
• The hemi-covers fit in four points (tongue and groove), what will keep them joined 
providing more stability to the small setup, as for the external cover. However in this 
case the junction points have a diameter of 0.8cm. 
18,00cm 
20,00cm 
Internal cover (C
I1
, C
I2
) 
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0,60cm 
Scheme of the internal cover 
17,97cm 
4,92cm 
distancia 
entre centros 
6,00cm 
17,97cm 
G1 
G2 
4,92cm 
Cylinders G – Plastic (G
1
; G
2
) 
• A hollow cylinder with 17.97cm of outer diameter (plus 0.03cm of film thickness, 
reach the internal cover’s inner diameter of 18cm), 8.13cm of inner diameter and 
20.30cm length, longitudinally cut by the central XZ plane, forming two symmetrical 
parts (hemi-cylinders G1 and G2). 
It allows up to 2 radiochromic films rolled up around the outer diameter (by the 
longer side of the film) and comprises its entire length (by the shorter side). 
Schemes of the plastic cylinder G 
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  Cylinders G – cork (G
11
, G
12
 ; G
21
, G
22
)  
• Two hollow cylinders with 17.97cm of outer diameter, 8.13cm of inner diameter and 
5cm length, longitudinally cut by the central XZ plane, forming 4 symmetrical parts 
(hemi-cylinders G
11
, G
12
 , G
21
, G
22
). 
Allow up to 2 radiochromic rolled up films (by the longer side of the film, by 
default) and comprises 10cm of film length. 
8,13cm 
17,97cm 
G
11
 
G
12
 
G
21
 
G
22
 
G
11
 
G
12
 
G
21
 
G
22
 
Schemes of the cork cylinders 
G 
Cylinders G – plastic and cork 
References for localization:  
Longitudinal – for plastic and cork: at the center, one upper and one lower; 
Front - for plastic and cork : at 0°, 45°, 135°, 180°, 225° and 315°;  
Axial – for plastic: two at 12,5cm from the edge, one around the cylinder, which 
matches with the axial of the covers (the phantom's half) when the cylinder is placed at 
the front end, and the inner axial reference. 
17,97cm 
4,92cm 
8,13cm 
17,97cm 
Lower 
longitudinal 
reference (not 
represented) 
0° 
45° 
315° 
135° 
180° 
225° 
Upper longitudinal 
reference Axial reference 
(at 12,5cm) 
Lower 
longitudinal 
reference (not 
represented) 
Front 
references 0° 
45° 
315° 
135° 
180° 225° 
Inner axial 
reference 
Representation of references (in red) for plastic and cork cylinders G 
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 One cylinder with 8.10cm of diameter and 20.30cm length, longitudinally cut by the 
central XZ plane, forming 2 symmetrical parts (hemi-cylinders).  
 References for localization: the same as the plastic cylinder G (see above). 
Cylinders P – plastic (P
1
 ; P
2
) 
It allows to roll up 1 radiochromic film (by the longer side, by default) 
and comprises its entire length (by the shorter side). 
P1 
P2 
Schemes of the plastic cylinder P with references depicted in red  
Cylinders P – cork (P
11
, P
12
 ; P
21
, P
22
)  
• Two cylinders with 8.10cm of diameter and 5cm length, longitudinally cut by the 
central XZ plane, forming 4 symmetrical parts (hemi-cylinders P
11
, P
12
 , P
21
, P
22
).  
• References for localization: the same as cork cylinders G (see above). 
Allow to roll up 1 radiochromic film (by the longer 
side of the film) and comprise 10cm of film length. 
P
11
 
P
22
 
P
21
 
P
12
 
P
11
 P
22
 
P
21
 
P
12
 
Schemes of the cork cylinders P with references depicted in red  
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  Slices (R1-9 of 1cm; R10-11 of 0,5 cm; R12-13 of 2,5cm) 
• Thirteen slices of different thickness, with 18.0cm diameter, allowing the irradiation 
of axial films of 12.7 x 12.7 cm
2
, inscribed in the slices (see 2D image). 
• Both 2.5cm slices are holed in the same way as the front internal lid, with holes of 
the same dimensions, in order to match once closed. 
Film inscribed 
in one slice 
Internal cover 
R1-9 
R10-11 
R12-13 
Amounts and thicknesses: 
- 9 Slices of 1,00cm thickness; 
- 2 Slices of 0,5cm thickness;  
- 2 Slices of 2,5cm thickness 
       (Holed as the T
I1
). 
View of the outside part of the lid with screws 
 Two external lids of 1cm, front (T
E1
) and back (T
E2
), are screwed to the external cover, 
allowing their closing through 8 perforations. Closer to their center, they present 4 
housings for the screw heads of the internal covers, which go up to the half of their 
thickness (0.5 cm depth). 
View of the inside part of the lid 
External lids (T
E1
, T
E2
) 
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  External lids (T
E1
, T
E2
) 
Outside (a) and inside (b) views of one of the external lids 
18,00cm 18,00cm 
b) a) 
Housing for the 
screw head 
0,5cm depth 
These housings for screw heads have 
circular shape and not hexagonal as 
shown in the figure (simply it is represents 
their location and depth). Their diameters 
correspond to the screws head of 0.8cm 
diameter and circular head. 
Internal lids (T
I1
, T
I2
) 
 Two internal lids, the front one (T
I1
) of 1.5cm thickness and the back one (T
I2
) of 
1.2cm, are screwed to the internal cover, allowing their closing through 4 
perforations. The front lid (T
I1
) allows the introduction of the prism shaped inserts into 
the phantom at its center and near to its edge.  
Outside (a) and inside (b) views 
of the front internal lid (T
I1
) 
a) 
b) 
b) 
a) 
Outside (a) and inside (b) views 
of the back internal lid (T
I2
) 
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  Front internal lid (T
I1
) 
18,00cm 
20,00cm 
0.6cm 
Distance between centers 
6,0cm 
20,00cm 
b) 
Outside (a) and inside (b) views of the front internal lid (TI1) 
a) 
Internal lids (T
I1
, T
I2
)  
 References for localization: 
 Front internal lid (T
I1
): a cross mark at 0° and other rotated at 45°, therefore it has a 
mark each 45°; 
 Back internal lid (T
I1
): cross mark at 0°. 
Representation of references (in red) of the two internal covers TI1 and TI2  
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Zenithal view with dimensions of the cork cylinders; plastic slices and lids. 
BE
V
Back Lids 
Front Lids 
Internal 
Cover 
Zenithal view with dimensions of the cork cylinders; 
plastic slices and lids (without internal cover). 
BEV 
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Zenithal view with dimensions of the plastic cylinders; 2.5cm slices and lids. 
BEV 
Back Lids 
Front Lids 
Internal 
Cover 
BEV 
Zenithal view with dimensions of the plastic cylinders; 
2.5cm slices and lids (without internal cover) 
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  Supports (S
1
, S
2
) 
 The phantom will be placed on two 
identical supports, the front one and back 
one (S
1
, S
2
), as shown in the figure.  
S
2
 S
1
 
Supports (S
1
, S
2
) 
 Each support is formed by one plinth (blue) and two bases (yellow), which would be 
used alternately, depending on the intended setup type (big or small). Both plinths 
provide the possibility of leveling the phantom through 4 outermost screws, which in 
turn also allow to fix each one of the bases to the plinth. This plinth also has a central 
screw that overpasses the support as a pin, and screw the covers (external or 
internal), for their fixation. 
Big Setup 
 
 
 
 
External Cover 
Small Setup 
 
 
 
 
 
Internal Cover 
Support plinths 
Support 
bases 
Jackscrews 
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  Supports (S
1
, S
2
) - plinths 
Scheme of one jackscrew:  
- Amount (6)  
- Thread pitch of 0.1cm 
Schemes of the plinths of S1 and S2:  
- Both external holes with thread pitch of 0.1cm 
- Central hole without thread pitch 
Supports (S
1
, S
2
) - bases 
For both bases: 
- All holes of 1.00cm diameter;  
- The two outermost holes with 
thread pitch of 0.1cm; 
- Central hole without thread pitch. 
Scheme of the base for big setup, which 
is screwed to the external cover. 
- Amount (2) 
Scheme of the base for small setup, 
which is screwed to the internal cover. 
- Amount (2) 
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  Inserts (I
1,2
 ; I
3,4
 ; I
5-8 
; I
9-11 
; I
12-18
) 
• Six inserts to fill the cylinders in plastic and cork version (I
1,2
, I
5-8
). Three of them are cut 
longitudinally (hemi-prisms), which fill the small cylinders, allowing to place a coronal film in 
between. 
• Two inserts to fill the 2.5cm slices (I
3,4
).  
• Three inserts for housing different types of ionization chamber (I
9-11
) and the remaining seven 
of different length to be used with the chambers (I
12-18
).  
To center the chamber in the 
phantom a chamber insert is used 
along with the insert of 7.8cm, the 
chamber’s tip thus stays located at 
the phantom’s isocenter (touching 
the edge of the insert of 7.8cm). 
The table should be moved to place 
the chamber at its effective point. 
Some of the considered chambers:  
PTW Semiflex type 31010 
(0,125cm
3
) & PinPoint; Wellhofer 
CC13 (0,13cm
3
), … 
Chamber’s 
tip 
Insert for 
chamber 
housing 
Phantom’s center 
reference 
Insert of 
7,8cm 
Inserts for slices and cylinders: 
Inserts (I
1,2
 ; I
3,4
 ; I
5-8
)  
I
3
 , I
4
 – Entire plastic prisms 
- Amount (2) 
I
5
 , I
6
 – Cork prisms longitudinally cut 
- Amount (2)  
I
1
 - Plastic prism longitudinally cut 
- Amount (1)  
I
7
 , I
8
 - Entire cork prisms  
- Amount (2)  
I
2
 – Entire plastic prism  
- Amount (1) 
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Inserts for ionization chambers: 
Inserts (I9-11 ; I12-18) 
 
I
9 
– Semiflex I.C.  
Amount: (1) 
I
10 
–PinPoint I.C. 
Amount: (1) 
I11 –Wellhofer I.C.  
Amount: (1) 
Inserts I12-18 of different lengths 
for chambers placement 
Amount: (1) 
(2) 
(2) 
(1) (1) 
Inserts for ionization chambers: 
Insert (I9) 
 
5 
Transparency of the insert I9 for Semiflex I.C. 
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  Inserts for ionization chambers: 
Insert (I10) 
 
5 
Transparency of the insert I
10
 for PinPoint I.C. 
Inserts for ionization chambers: 
Insert (I11) 
 
5 
Transparency of the insert I11 for Wellhofer I.C 
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